Immunological materials and methods for detecting dihydropyrimidine dehydrogenase

ABSTRACT

Monoclonal antibodies against dihydropyrimidine dehydrogenase are disclosed. Immunologic assays using the monoclonal antibodies are also disclosed.

REFERENCE TO RELATED APPLICATION

[0001] This application is a divisional of U.S. Serial No. 09/138, 103 filed Aug. 21, 1998.

BACKGROUND OF THE INVENTION

[0002] The present invention relates to immunological materials and methods useful for the determination of dihydropyrimidine dehydrogenase (DPD) in biological samples.

[0003] Dihydropyrimidine dehydrogenase (DPD) is an enzyme which catalyzes the reduction of pyrimidines to 5,6-dihydropyrimidines, where the resulting catabolites, dihydrouracil and dihydrothyrnine, are further catabolized to β-alanine or β-aminoisobutylic acid, respectively.

[0004] DPD is also known to catalyze the reducing reactions of 5-fluorouracil (5-FU) and various catabolites from pyrimidine analogues and derivatives, which are widely utilized as antitumor medicines, such as 2′-deoxy-5-fluorouridine (2′-dFUrd), 5′-deoxy-5-fluorouridine (5′-dFUrd, doxifluridine), and the like. It has been reported that the DPD level in biological samples of individuals suffering from tumor is an interesting marker of the therapeutic efficacy of antitumor medicaments in the series of 5-fluorouracil derivatives (see e. g. Iigo et al., 1969, Biochem. Pharmacol., 38, 1885-1889).

[0005] Deficiency in DPD is known to be responsible for the toxicity of the metabolites of pyrimidine antitumor medicines, which results in life-threatening condition during chemotherapy (Milano, G. and Etienne, 1988, M. C., Pharnacogenetics, 4, 301-306). Recently it was found that the disorder of DPD deficiency is more frequent than initially thought (Diasio and Lu, 1994, J. Clin. Oncol., 12, 2239-2242). It is thus important to identify patients with DPD deficiency.

[0006] There is therefore a need for a sensitive and reliable assay for the determination of the DPD level in biological samples.

[0007] Several methodologies for such assays have been described. Fernandez-Salguero et al. reported a thin layer chromatography (TLC) procedure for the determination of DPD activity in human peripheral lymphocytes (Fernandez-Salguero et al., 1995. Biochem. Pharm. 50, 1015-1020). The assay uses radiolabeled uracil as a substrate. However, a method which uses a radiolabel is obviously not adapted to routine diagnosis in hospitals. Furthermore, such a TLC method is time-consuming.

[0008] Other assay methods utilizing HPLC have been also described, e.g. by van Gennip et al., 1982, Adv. Exp. Med. Biol., 253A: 111-118, and Sommadossi et al., 1982, J. Biol. Chem., 257: 8171-8176. Those methods are based on the measurement of enzyme activity by the determination of the sum of various catabolites of 5-FU using reverse phase HPLC. Such methods are cumbersome and time-consuming.

[0009] The problem addressed by the present invention is to find materials and methods for the determination of DPD level that do not have the drawbacks of the above known methods, and that provide a simple and speedy assay for routine use in hospitals.

SUMMARY OF THE INVENTION

[0010] The above problem is solved by the invention as defined in the appended claims.

[0011] The present invention provides a monoclonal antibody specifically recognizing dihydropyrimidine dehydrogenase (DPD), and particularly human dihydropyrimidine dehydrogenase.

[0012] The above monoclonal antibody is suitably a monoclonal antibody that shows strong reactivity to a homogenate from human tumor cell line HT-3 (ATCC HTB-32), but a low reactivity or no reactivity to a homogenate from human tumor cell line MCF-7 (ATCC HTB-22).

[0013] The above monoclonal antibody is a monoclonal antibody that shows a high specificity for DPD.

[0014] Suitably the immunoprecipitate obtained with a homogenate from human tumor cell line HT-3 (ATCC HTB-32) will show a single band when analyzed by SDS-PAGE.

[0015] The monoclonal antibody can suitably be produced by a hybridoma cell line selected from the group consisting of hybridoma cell lines 2B6-11-1, 9C7-30-1, 5E6-19-1, 3A5-6-1 (FERM BP-6015), 6H5-42-1, 4B9-12-1 (FERM BP-6016), 2E2-B3-1-3 (FERM BP-6014) and 3B12-B1-56-1-2. Preferably the monoclonal antibody is one produced by a hybridoma cell line chosen among 3A5-6-1 (FERM BP-6015), 4B9-12-1 (FERM BP-6016), 2E2-B3-1-3 (FERM BP-6014).

[0016] The monoclonal antibody can also be any monoclonal antibody that binds to DPD in an equivalent manner as a monoclonal antibody produced by one of the above cell lines, i.e. a monoclonal antibody which binds to the same epitope as a monoclonal antibody produced by one of the above cell lines or crossreacts strongly with a monoclonal antibody produced by one of the above cell lines.

[0017] The invention also concerns a hybridoma cell line producing the above defined monoclonal antibody.

[0018] That hybridoma cell line is suitably chosen from the group consisting of hybridoma cell lines 2B6-11-1, 9C7-30-1, 5E6-19-1, 3A5-6-1 (FERM BP-6015), 6H5-42-1, 4B9-12-1 (FERM BP-6016), 2E2-B3-1-3 (FERM BP-6014) and 3B12-B1-56-1-2, and preferably a hybridoma cell line chosen among 3A5-6-1 (FERM BP-6015), 4B9-12-1 (FERM BP-6016), 2E2-B3-1-3 (FERM BP-6014).

[0019] The present invention also relates to a pair of monoclonal antibodies which is useful for the qualitative and/or quantitative detection of DPD, wherein the pair comprises a first monoclonal antibody specifically recognizing dihydropyrimidine dehydrogenase and a second monoclonal antibody specifically recognizing dihydropyrimidine dehydrogenase, wherein the first monoclonal antibody and the second monoclonal antibody recognize different epitopes from one another.

[0020] Such a pair of monoclonal antibodies can include as first monoclonal antibody, a monoclonal antibody selected from the group consisting of Mab-3A5-6-1, Mab-6 H5-42-1 and Mab-3B12-B1-56-1-2, and as second monoclonal antibody, a monoclonal antibody selected from the group consisting of Mab-4B9-12-1, Mab-2E2-B3-1-3, Mab-9C7-30-1, Mab-2B6-11-1 and Mab-5E6-19-1.

[0021] Preferably the first monoclonal antibody is Mab-3A5-6-1, and the second monoclonal antibody is Mab-4B9-12-1 or Mab-2E2-B3-1-3.

[0022] Further the present invention relates to kit for the detection and/or determination of the amount of dihydropyrimidine dehydrogenase in a biological sample which comprises

[0023] (a) at least one monoclonal antibody as defined above, and

[0024] (b) a label for qualitatively and/or quantitatively detecting the immunoconjugate of the monoclonal antibody and dihydropyrimidine dehydrogenase.

[0025] Preferably that kit comprises a pair of monoclonal antibodies and a label as defined above.

[0026] In another aspect, the invention relates to an immunoassay method for detecting and/or determining the amount of dihydropyrimidine dehydrogenase in a biological sample which comprises

[0027] (a) treating the sample with at least one monoclonal antibody as defined above, so to produce an immunoconjugate between that antibody and dihydropyrimidine dehydrogenase, and

[0028] (b) qualitatively or quantitatively detecting the said immunoconjugate with the aid of a label.

[0029] The immunoassay can be of any immunoassay format known in the art of immunoassays (see e.g. M. Ferencik, 1993, in “Handbook of Immunochemistry”, published by Chapman & Hall, London, UK). In particular it can be one-point binding assay, e.g. an immunoprecipitation method, or a two-point binding assay (sandwich assay), e.g. an ELISA. A two-point binding assay will preferably use a pair of monoclonal antibodies as defined above.

[0030] In a further aspect the invention relates to a method for the determination of the DPD deficiency state of a patient which comprises; (a) treating a biological sample from the patient with a monoclonal antibody as defined above, and (b) quantitatively detecting the immunoconjugate of the monoclonal antibody and dihydropyrimidine dehydrogenase.

[0031] In another aspect the invention concerns a method for estimating the susceptibility of patients suffering from cancer to the treatment with antitumor medicaments in the series of 5-fluorouracil (5-FU) derivatives, which comprises

[0032] (a) treating a biological sample from the patient with a monoclonal antibody as defined above,

[0033] (b) quantitatively detecting the immunoconjugate of the monoclonal antibody and human dihydropyrimidine dehydrogenase, so as to determine the level of dihydropyrimidine dehydrogenase in the biological sample from the patient to obtain a measure of susceptibility.

[0034] The above method enables the physician, by comparing that measured level of DPD for a patient to that of a reference set of patients, to predict the efficacy and toxicity of the above medicaments.

[0035] In further aspect the invention concerns a method for estimating the susceptibility of patients suffering from cancer to the treatment with antitumor medicaments in the series of 5-fluorouracil (5-FU) derivatives, which comprises

[0036] (a) treating a biological sample from the patient with a monoclonal antibody as defined above,

[0037] (b) quantitatively detecting the immunoconjugate of the monoclonal antibody human and dihydropyrimidine dehydrogenase, so as to determine the level of dihydropyrimidine dehydrogenase in the biological sample from the patient,

[0038] (c) determining the level of pyrimidine nucleoside phosphorylase in the said biological sample from the said patient, and

[0039] (d) calculating the ratio of the level of pyrimidine nucleoside phosphorylase and the level of dihydropyrimidine dehydrogenase to obtain a measure of susceptibility.

[0040] The above method enables the physician, by comparing that calculated ratio of the level of pyrimidine nucleoside phosphorylase and the level of dihydropyrimidine dehydrogenase for a patient and that of a reference set of patients, to predict the efficacy of the above medicaments.

BRIEF DESCRIPTION OF THE FIGURES

[0041]FIG. 1 illustrates the confirmation of the antigenicity of the recombinant GST-DPD fusion proteins produced in Example 1 by Western Blotting with anti-DPD Peptide 2 antibody. In FIG. 1, lane 1 is molecular weight marker, lane 2 is GST protein per se, lane is GST-DPD fusion protein.

[0042]FIG. 2 illustrates the pattern of the Western Blot of the monoclonal antibodies of the present invention against human tissue homogenates containing DPD. In this Figure, lane is for molecular weight marker; lane 2 is for recombinant DPD (rDPD); lane 3 is for a xenograft homogenate of a human tumor cell line, HT-3; and lanes 4, 5 and 6 are for the different human lung carcinoma homogenates, respectively.

[0043]FIG. 3 illustrates a calibration curve obtained by the ELISA according to the invention which is described in Example 3. In this Figure, the horizontal axis is for logarithm of the HT-3 activity and the perpendicular axis is for logarithm of optical density (OD) measure at the wave length of 450 nm. FIG. 3 shows that the ELISA of the present invention enabled the determination of the DPD activity over the range from about 2.5 to about 170 pmol/minute/ml.

[0044]FIG. 4 illustrates the correlation between DPD levels detected by a DPD activity assay and the ELISA of the present invention in both normal tissues and tumor tissues of breast. The DPD activity assay is conducted by a conventional TLC method using ¹⁴C-radioactive label. The ELISA used here is that described in Example 3.

[0045]FIG. 5 illustrates the results of the study of the susceptibility to antitumor medicaments in the series of 5-fluorouracil (5-FU) derivatives, such as FURTULON, by determining PyNPase/DPD ratios as described in Example 5. PyNPase levels were assayed by using the method described by Nishida M. et al., 1996, Biol. Pharm. Bull. 19(11), 1407-1411. The ELISA used here is that described in Example 3.

[0046]FIG. 6 illustrates the results of an immunoprecipitation assay using monoclonal antibodies according to the present invention as described in Example 6.

[0047]FIG. 6-1 (a) and (b) show the results of SDS-PAGE, where (a) is for the supernatants and (b) is the bead eluates of the immunoprecipitates. FIG. 6-2 (a), (b) and (c) show results of Western blotting, where (a) is the result obtained from the supernatant detected using anti DPD-1 polypeptide antibody, (b) is the result from the elutions from the immunoprecipitates detected by using anti DPD-1 polypeptide antibody, and (c) show the result from the same elutions as (b) in which the monoclonal antibody 3A5-6-1 of the present invention was used for the detection. The respective lanes correspond to the results of the immunoprecipitation assay using the following samples: lane 1: mouse IgG1; lane 2: 2B6-11-1; lane 3: 2E2-B3-1-3; lane: 4B9-12-1; and lane 5: 9C7-30-1. The lane c in FIG. 6-2 (b) is the run of homogenate of HT-3 as a positive control.

DETAILED DESCRIPTION OF THE INVENTION

[0048] Preparation of Monoclonal Antibodies

[0049] The methodology for the production of a monoclonal antibody to a specific antigen is well known in the art and described e.g. by Harlow et al., 1988, Section 6 of “Antibodies: a Laboratory Manual”, Cold Spring Harbor Press, New York, USA.

[0050] Hybridoma cell lines which produce monoclonal antibodies recognizing specifically DPD are first established. For this purpose, an experimental animal is immunized with the DPD protein or fragments thereof as antigens. The experimental animal can be of any species possessing immunocompetent cells such as lymphocytes and spleen cells apt to be used to establish a hybridoma cell line. Suitable species are for instance mouse, rat, rabbit and goat. Mouse or rat is particularly convenient. The antigen may be the DPD protein per se or fragments thereof including a mixture of such fragments. The DPD protein or fragments thereof used as antigens can be obtained either by isolating the protein from a natural source or by producing with the aid of recombinant technology. The DPD protein can be obtained from natural source, such as liver tissues, preferably from human, by the isolation method as already reported e.g. by Lu et al. in J. Biol. Chem. 267, 17102-17105, 1992.

[0051] Genetic recombinant technology provides a convenient means for the preparation of recombinant antigens. The information of nucleotide sequence of human. DPD is available from GenBank™/EMBL Data Bank with accession number U09179 (see Yokota, H. et al., 1994, J. Biol. Chem. 269, pp. 23192-23196). The nucleotide sequence of human DPD and the amino acid sequence deduced therefrom are set forth in the sequence listing hereinbelow as SEQ ID NO: 1 and SEQ ID NO: 2, respectively. Based on this sequence information, a recombinant DPD protein or a fragment therof can be produced using either a synthetic DNA or a cloned DPD gene with the aid of conventional expression systems for recombinant gene. When cloning is desired, the cloning strategy can based on any nucleic acid amplification method e.g. using polymerase chain reaction (PCR), ligase chain reaction (LCR), transcription amplification or self-sustained sequence replication. Polymerase chain reaction (PCR) is particularly reliable and convenient. PCR cloning strategy can provide the full nucleotide sequence of the DPD gene or the partial nucleotide sequence of that gene. It is shown in the Examples that a fragment of DPD in a form of a fusion protein with GST protein is an effective antigen for immunizing an animal.

[0052] The amino acid sequence as described in SEQ ID NO: 2 provides useful information for the chemical synthesis of DPD fragment(s). Such synthetic peptides are also useful as an antigen for the present invention. The antigens prepared by either of the above methods can be evaluated for their antigenicity by Western blotting.

[0053] By the injection of the said antigen into a mouse, rat, sheep, rabbit or the like. monoclonal antibodies of the present invention can be prepared by recovering antibody producing cells from such an immunized animal and immortalizing the said cells. The immunization of the animals with the above antigen can be conducted by procedures well known in the art, described e.g. by the above reference of Harlow et al. The immortalization provides hybridoma cell lines producing monoclonal antibodies, and may be conducted in conventional fashion like fusion of the antibody producing cells with myeloma cells.

[0054] Supernatants of the culture of such hybridomas are screened for monoclonal antibodies by conventional procedure like dot-immunobinding assays, such as Western blotting, or radio-immunoassays, enzyme immunoassays or the like.

[0055] Monoclonal antibodies can be purified from hybridoma supernatants by conventional chromatographic procedures, for example ion exchange chromatography, affinity chromatography on protein G or protein A, HPLC or the like.

[0056] For the production of large quantities of monoclonal antibodies in accordance with methods well-known in the art, hybridomas secreting the desired antibody can be injected intraperitoneally into mice which have been pretreated with pristane before injection. Up to around 100 mg of a monoclonal antibody can be produced by such ascites tumors in one mouse. Monoclonal antibodies can be purified for example from ascites fluid produced by such tumors as described in Example 2.

[0057] Monoclonal antibodies can be characterized according to their subclass by known methods such as Ouchterlony immunodiffusion, or using a commercially available test kit, such as Mouse Mono Ab-ID EIA Kit (Zymed, San Francisco, Calif., USA). In the present invention, the subclass of the particular monoclonal antibodies from the hybridoma cell lines prepared in Example 2 were determined to be Mab-2B6-11-1 (IgG 1, κ), Mab-9C7-30-1 (IgG1, κ), Mab-4B9-12-1 (IgG1, κ), Mab-2E2-B3-1-3 (IgG1, κ), MabMab-5E6-19-1 (IgG3, κ), Mab-3A5-6-1 (IgM, κ), Mab-6H5-42-1 (IgM, κ), Mab-3B 12-B1-56-1-2 (IgM, κ), respectively.

[0058] The hybridoma cell lines according to the invention designated as 4B9-12-1, 3A5-6-1 and 2E2-B3-1-3 are particularly useful for the production of the monoclonal antibodies of the present invention, particularly for multisite binding assays. Those cell lines were deposited at the National Institute of Bioscience and Human-Technology (NIBHT) Agency of industrail Science and Technology, M.I.T.I. Higashi, Tsukuba, Japan on Jul. 8, 1997 in accordance with the Budapest Treaty with the following accession numbers: FERM BP-6014 for 2E2-B3-1-3, FERM BP-6015 for 3A5-6-1 and FERM BP-6016 for 4B9-12-1.

[0059] The monoclonal antibodies of the present invention can be used for the immunoaffinity purification of DPD. Such antibodies can to that end be linked to solid supports by methods well-known in the art, for example by covalent binding to CNBr activated agarose, such as Sepharose, or the like.

[0060] Furthermore, the monoclonal antibodies of the present invention can also be used as diagnostic tools for the determination of DPD level in a biological samples which may be tumor tissues of human patients. For such use, monoclonal antibodies may be coupled to a fluorescent dye, a color producing substance, like an enzyme (enzyme linked immunosorbent assay: ELISA) or a label conventionally used in the art, such as biotin.

[0061] For the purpose of investigating the performance of the assay format which can be constructed by the use of monoclonal antibodies of the present invention, the following conventional assay, which utilizes radioisotope, may be used.

[0062] Assay Method of DPD Enzymatic Activity

[0063] The enzyme activity of DPD can be determined by measuring the sum of the 5-FU catabolites, i.e. dihydrofluorouracil, (α-fluoro-β-ureidopropionate, and (αfluoro-β-alanine, formed from [6-¹⁴C] 5-FU. The following procedure can be applied to the above assay:

[0064] The standard reaction mixture contains 10 mM potassium phosphate (pH 8.0), 0.5 mM EDTA, 0.5 mM 2-mercaptoethanol, 1 mM dithiothreitol, 2.5 mM MgCl₂, 250 μM NADPH, 25 TM [6-¹⁴C]5-FU (56 mCi/mmol), and 25T1 crude enzyme (final protein concentration: 1 mg/ml) in a total volume of 50 T1. The reaction is carried out at 37° C. for 30 minutes and then terminated by immersing the reaction tubes (0.5 n-d Eppendorf tubes) in a boiling water bath for 30 minutes. The reaction tubes are frozen at −20° C. for at least 20 minutes before further manipulations are undertaken. Proteins are removed by centrifugation, and then the 10 T1 of the supernatant fluid are spotted on silica gel TLC sheets (MERCK 5735) which are prespotted with 5 T1 of authentic markers mixture of 10 mM 5-FU, 50 mM dihydrouracil, 20 mM β-ureidoproplonate, 10 mM α-fluoro-β-alanine, and 50 mM urea. The spots are developed in a solvent system of a mixture of ethylacetate/isopropanol/H₂O (65:23:12, v/v/v). These markers developed are identified by the methods of Naguib et al., 1985, Cancer Res. 45, 5405. The radioactivity of the spots identified as the 5-FU catabolites can be detected by BAS 1000 System (FUJI Film). DPD activity is expressed as pmol 5-FU converted/mg protein/minute.

[0065] Enzyme linked immunosorbent assay (ELISA)

[0066] As typical application of the monoclonal antibodies of the present invention in immunological quantitative assays, a one-point binding method and two-point binding method (so called sandwich assay) are contemplated. It can generally be said that two-point binding methods are advantageous in achieving higher accuracy and higher sensitivity. An ELISA using a pair of monoclonal antibodies as defined above proved to be a sensitive and quick assay format (see Example 3).

[0067] That ELISA can be performed by immobilizing one of the antibodies onto a solid carrier, subjecting thus immobilized antibody to contact with a sample suspected to contain DPD to form a DPD-antibody conjugate, reacting this conjugate with the other monoclonal antibody to form a DPD sandwiched conjugate, i.e. antibody-DPD-antibody, and labeling the latter conjugate, for example by HRP labeled rat anti-mouse immunoglobulin antibody, to detect the conjugate. In case that HRP label is used, detection can be performed by coloring reaction using, for example TMB microwell peroxidase kit system (KPL) which contains TMB and H₂O₂ as a substrate developing color in the enzymatic reaction catalyzed by HRP. As a label for detection, the rat anti-mouse immunoglobulin antibody may have any conventional label, such as biotin, an enzyme, a radioisotope and the like. Alternatively, the monoclonal antibody in mobile phase may be labeled with HRP, biotin, radioisotope, latex particle and the like.

[0068] As shown in Example 3, a high sensitivity of the ELISA can be attained using the above defined pair of monoclonal antibodies. That high sensitivity makes the assay useful for determining the DPD level in biological samples from human body, even in case of a low level of DPD, as in the above described condition of DPD deficiency.

[0069] Immunoprecipitation

[0070] The monoclonal antibodies according to the invention are also useful for isolation and determination of the DPD protein by an immunoprecipitation method. The methodology of immunoprecipitation itself is well known in the art. Using a monoclonal antibody as defined above it provides the specific separation of the target antigen (DPD) from a complex sample due to the high binding specificity of that monoclonal antibody.

[0071] One of the typical precipitating agents which can be used, is Protein G-Sepharose 4B, wherein Protein G capable of binding to the Fc region of mouse immunoglobulin is immobilized on the surface of Sepharose 4B beads. This agent forms a complex of DPD-antibody-Protein G-Sepharose beads, when DPD is present, and the complex can be separated by centrifugation. From the collected precipitate of the complex, the antigen (DPD) and antibody can be dissociated under an acidic condition, such as in a glycine-HCl-buffer, pH 3.0. Thus separated DPD can be readily isolated from immunoglobulin with the aid of gel filtration. Such complex to which DPD is bound is useful not only for the isolation of this enzyme but also for the quantification of the enzyme. Thus the monoclonal antibodies of the present invention are potent tools for the isolation and determination of DPD from a complex biological samples as is shown in Example 6 below.

[0072] Antibody Capture Assay

[0073] The monoclonal antibodies of the present invention are also useful in the antibody capture assay. In this assay format, the monoclonal antibody is immobilized on. surfaces of an appropriate container, such as the wells of microtiter plate. Immobilization is performed by a conventional method known in the art. When a sample containing DPD is added to such wells, the DPD peptide is captured by the immobilized monoclonal antibody of the present invention. After washing the wells a solution containing the substrate of DPD is added. Thus the detection system of enzymatic product will provide a determination means of DPD activity. This assay format will be useful to determine whether the captured DPD has its intact enzymatic action, since the patients carrying genetic defects on the DPD gene may have mutated DPD proteins which lack enzymatic activity.

[0074] Alternatively, after DPD is captured by the immobilized monoclonal antibody, such immuno complex is washed and then DPD polypeptide is eluted by an appropriate buffer solution, for example under acidic condition. This manipulation also provides a purified DPD preparation.

[0075] Abbreviations

[0076] The following abbreviations will be used hereinbelow.

[0077] DPD: dihydropyrimidine dehydrogenase

[0078] PyNPase: pyrimidine nucleoside phosphorylase

[0079] GST: glutathione S-transferase

[0080] IPTG: isopropyl β-D-thiogalactopyranoside

[0081] KLH: keyhole limpet hemocyanin

[0082] 5-FU: 5-fluorouracil

[0083] CFA: complete Freund's adjuvant

[0084] WFA: incomplete Freund's adjuvant

[0085] EIA: enzyme immuno assay

[0086] ELISA: enzyme linked immunosorbent assay

[0087] TLC: thin layer chromatography

[0088] PBS: phosphate buffered saline

[0089] PCR: polymerase chain reaction

[0090] TMB: tetramethylbenzidine

[0091] (TMB: kit contains 3,3′, 5,5′-tetramethylbenzidine and H₂O₂.)

[0092] TBS: Tris-buffered saline (20 mM Tris/50 mM NaCl, pH 7.4)

[0093] TTBS: TBS containing 0.05% TWEENO®-20

[0094] The present invention will be further illustrated by the following examples. The following description will be better understood by referring to the following FIGS. 1, 2, 3, 4, 5, 6-1 and 6-2.

EXAMPLE 1

[0095] Preparation of Antigens

[0096] As described previously, the nucleotide sequence of human DPD and the amino acid sequence deduced therefrom were reported by Yokota, H. et al., 1994, J. Biol. Chem., 269, (37) 23192-23196 (see SEQ ID NO: 1 and SEQ ID NO: 2). A fusion protein as an antigen was prepared based on the genetic information from the position 1770 to the position 3164 of SEQ ID NO: 1, which fusion protein was expressed as GST-DPD fusion protein with the aid of a host organism E. coli JM 109 transformed with the vector pGEX 4 T-3 carrying the said genetic information as described below.

[0097] 1) Construction of a DPD Expression Vector

[0098] On the basis of the genetic information of the position 1770-3164 of SEQ ID NO: 1. three DNA primers were prepared for the purpose of cloning a segment of the DPD gene by polymerase chain reaction (PCR). Primer 1 (Eco RI linker+sense) was prepared as a 25-mer having a sequence consisting of an Eco RI linker (CGCGAATTC) at the 5′-end portion and a positive strand corresponding to nucleotides 1770-1785 of SEQ ID NO: 1. Primer 1: 5′-CGCGAATTCTTTTGAAGCTGGATGG-3′ (SEQ ID (1770 Eco RI linker + sense) NO: 3)

[0099] Primer 2 (Eco RI linker+antisense) was prepared as a 26-mer having a sequence consisting of an Eco RI linker at the 5′-end portion and a negative strand complementary to nucleotides 3148-3164 of SEQ ID NO: 1. Primer 2: 5′-CGCGAATTCTCACCTTAACACACCGG-3′ (SEQ ID (3164 Eco RI linker + antisense) NO: 4)

[0100] Primer 3 (antisense) was prepared as a 16-mer having a sequence complementary to the sequence corresponding to nucleotides 3495-3510 of SEQ ID NO: 1. Primer 3: 5′-AATCAAATATGGAGCA-3′ (SEQ ID NO: 5) (3510 antisense)

[0101] Total RNA was prepared from human lung diploid cell line WI 38 cell (ATCC CLL-75) by a conventional method using RNA Isolation Kit (Stratagene, La Jolla, Calif., USA) based on the acid guanidinium thiocyanate phenol chloroform extraction (AGPC) method (see e.g. Chomczynski, P. and Sacci, N., 1987, Anal. Biochem. 162, 156-159), and was subjected to reverse transcription reaction of reverse transcriptase RAV-2 using Primer 3 to obtain a cDNA preparation. In the reaction, 1 μg of the total RNA was subjected to the reverse transcription reaction in 20 81 of the reaction solution at 42 ° C for 60 minutes, and after reverse transcriptase was denatured by heating at 95° C. for 5 minutes. The cDNA preparation thus obtained was kept at 4° C. until use in PCR amplification. The buffer solution used in the synthesis of the first strand cDNA contained 5 mM MgCl₂, 1 mM each of dGTP, dATP, dTTP and dCTP, RNase inhibitor, 20 units of reverse transcriptase RAV-2 and 0.75 μM of the primers.

[0102] Then this cDNA preparation was subjected to PCR amplification using Primers 1 and 2 and a commercial PCR kit, namely RT-PCR Kit (Takara Shuzo, Shiga, Japan), according to the instructions of use of the kit with the exception that DNA polymerase (3.5 units of pfu) was used instead of Taq polymerase on an apparatus for thermal cyclization (ZYMOREACTOR II, ATTO, Tokyo, Japan). The buffer solution for PCR amplification having a total volume of 100 μl, contained 2 mM MgCl₂, 0.2 mM each of dGTP, dATP, dTTP and dCTP. and each 0.4 μM of the primers. The PCR program was 32 cycles of 94° C. for 30 s, 55° C. for 1 minute, and 75° C. for 4 minutes. Thus amplified DPD cDNA fragments were isolated by agarose gel electrophoresis as a band corresponding to 1.4 kbp, and then purified using QIAEX11 gel extraction kit (QIAGEN, Hilden, Germany). The purified cDNA fragment was digested with Eco RI and the Eco RI fragment was inserted into the Eco RI site of the vector pGEX4T-3 (Pharmacia, Uppsala, Sweden) using DNA Ligation Kit (Takara Shuzo, Shiga, Japan) at 16° C. overnight. Thus obtained vector (hereafter referred to as pGEX4T-3-DPD) was able to express a GST-DPD fusion protein. The partial nucleotide sequence of the above insertion fragment was determined and confirmed to have the expected subsequence of the DPD gene.

[0103] 2) Expression of GST-DPD fusion protein E. coli JM109 (Toyobo, Osaka, Japan) was transformed with pGEX4T-3-DPD, and the transformant was cultivated in the medium of SOB (20 g/l bacto-tryptone, 5 g/l bacto-yeast extract, 0.5 g/l sodium chloride, 0.186 g/l potassium chloride and 0.95 g/l magnesium chloride; pH 7.0) containing 50 μ/ml of ampicillin at the temperature of 22° C. to express the fusion protein. The cells of the said E. coli transformant were treated by the addition of 0.5 mM IPTG (isopropyl β-D-thiogalactopyranoside) and were incubated at 22° C. for about 16 hours, and subsequently subjected to sonification in a buffered solution containing 1% TRITONO®-X100, 1% sarcosyl, 10 mM DTT and 2 mM EDTA/PBS. The cell lysate was centrifuged, and the soluble fraction was applied to Glutathione-Sepharose 4B column (Pharmacia, Uppsala, Sweden). The adsorbed GST-DPD fusion protein was eluted by 10 mM of reduced glutathione. GST-DPD fusion protein was identified as an about 75 kDa protein on SDS-PAGE.

[0104] This fusion protein was confirmed by the reaction with an anti-DPD peptide antibody. For this purpose, two peptides of DPD, namely Peptide 1 (SEQ ID NO: 6) and Peptide 2 (SEQ ID NO: 7) were chemically synthesized based on the sequence described as SEQ ID NO: 2 and were coupled with KLH with the aid of the glutaralaldehyde method to obtain the antigens, as described e.g. by Harlow et al., 1988, in “Antibodies: a Laboratory Manual”, Cold Spring Harbor Press, New York, USA, pp 78-79. The respective antigens in the amount of 200 μg were subcutaneously injected together with CFA to rabbits to immunize the animals, followed by booster doses of the same amount of the antigens with IFA. The antisera thus produced were treated through a KLH column (which is a column wherein KLH is immobilized on a carrier, namely Affigel-10, available from BioRad, Hercules, Calif., USA) to remove anti-KLH antibodies and then purified by applying to Protein G column (MAB Trap GII, Pharmacia, Uppsala, Sweden) or a peptide column and eluting with a buffer of 0.1 M glycine-HCl, pH 3.0, followed by the neutralization with 1 M Tris HCl buffer, pH 8.0 before use. The peptide column was prepared by coupling the above mentioned Peptide 1 or Peptide 2 with Affigel-15 (BioRad, Hercules, Calif., USA). Both of these anti-DPD Peptide 1 and anti-DPD Peptide 2 polyclonal antibodies were reactive with DPD from human and mouse liver in the Western blotting, and thus were utilized to confirm the production of GST-DPD fusion protein. As described above, it was confirmed that the transformant produced the said GST-DPD fusion protein by the Western blotting with anti-DPD Peptide 2 (see FIG. 1). In FIG. 1, lane 1 was molecular marker, lane 2 is GST protein per se, lane 3 is GST-DPD fusion protein. As seen in lane 3, the fusion protein was confirmed to be a protein of about 75 kDa.

EXAMPLE 2

[0105] Preparation of Anti-DPD Monoclonal Antibodies

[0106] 1) Cell fusion

[0107] GST-DPD fusion protein prepared in Example 1 (50 μg per an animal) together with CFA was intraperitoneally injected to Balb/c mice in a volume of 100 μl/mouse, followed by intraperitoneal booster doses of about 10 μg per animal of GST-DPD protein together with IFA twice after the interval of two weeks. Three days after the final immunization, the sensitized mice were sacrificed to remove spleens, and spleen cells were prepared. The spleen cells thus obtained were carefully washed with the serum free RPMI 1640 medium (Nikken Seibutu Igaku Kenkyusho, Kyoto, Japan) which was pre-warmed at about 37° C. The subsequent fusion procedures were performed at about 37° C. using pre-warmed reagents including buffer solution.

[0108] Mouse myeloma cell line P3×63 Ag8-U1 (purchased from Flow Laboratories Ltd. Irvine, UK) were also carefully washed with the serum free RPMI 1640 medium. The spleen cells (about 4×10⁸) were mixed with the mouse myeloma cell line P3×63 Ag8-U1(8×10⁷) in the ratio of 5:1, and cell fusion was performed as follows. The mixture of the cells were pelleted by centrifugation, and the medium was aspirated, then to the pellet of the mixture of the cells, 250 μl of 50% polyethylene glycol solution (PEG1500, Boehringer Mannheim) was added slowly over 1 minute with stirring the pellet by the tip of the micropipet; subsequently another 250 μl of 50% PEG solution was added slowly over 1 minute with stirring the pellet by the tip of the micropipet; and then the stirring by gentle rotation of the tube was continued for 2 minutes. To the cell fusion mixture, 50 ml of serum free RPMI 1640 medium (Nikken Seibutu Igaku Kenkyusho, Kyoto, Japan) was slowly added dropwise over 5 minutes. and the cells were washed by centrifugation to remove PEG

[0109] The mixture of the cells pelleted after the cell fusion were re-suspended in a medium of RPMI 1640 (Nikken Seibutu Igaku Kenkyusho, Kyoto, Japan) containing 10% of fetal calf serum (FCS), penicillin/streptomycin and 2ME, and pipetted in to the wells of 96 well plates which then were incubated under 5% of CO₂ at 37° C. On the days 2th, 4th and 7th during the incubation, the half amount of the medium of each well was substituted by HAT medium (prepared by adding HAT solution (Flow Laboratories Ltd, Irvine, UK) to 10% FCS containing RPMI medium) and the incubation was continued. From about 10th day of the incubation, botryoid colonies were formed in some of the wells, and finally proliferation of hybridoma cells were observed in 1056 wells.

[0110] 2) Screening of monoclonal antibodies

[0111] (2-1) Primary Screening

[0112] All the wells exhibiting the proliferation of hybridomas were investigated by ELISA (Enzyme Linked Immunosorbent Assay) for positive wells as follows. The wells of 96 well immunoplates (Maxisorp, Nunc, Roskilde, Denmark) were coated with GST-DPD fusion protein or GST using the amount of 50 μl/well of the solutions containing 1 μg/ml of either protein. Non-adsorbed protein was washed out with TTBS and the blocking was effected by the incubation with TBS containing 3% skim milk for 1 hour. The wells were washed with TTBS again and were added with 50 μl/well of the hybridoma culture supernatant, and kept at 37° C. for 1 hour. After the respective wells were washed with TTBS three times, horse radish peroxidase (HRP)-labeled goat anti-mouse immunoglobulin IgG+A+M (KPL) was added and the plates were kept at 37° C. for 1 hour. The respective wells were washed with TTBS four times, and then a substrate (TMB, Microwell Kit System, KPL) was added. After the termination of the reaction by the addition of 1 M phosphoric acid, the absorption at 450 nm was measured using a microplate reader. The positive wells which reacted stronger with the coat of GST-DPD fusion protein than those of GST were gathered as the primary stock.

[0113] (2-2) Secondary screening

[0114] To ensure the efficiency of the screening, the secondary screening was performed by using a recombinant protein having the full sequence DPD in Western blotting.

[0115] (A) Preparation of a recombinant protein having the full sequence DPD

[0116] A recombinant protein of full sequence DPD was prepared by cloning the full length cDNA of DPD on the basis of RT-PCR cloning and by the expression of the gene inserted into an E. coli expression vector, pTrcHisA (Invitrogen, San Diego, USA), which method was essentially the same with that described in the case of the cloning and expression of GST-DPD fusion protein.

[0117] First, the first strand cDNA was prepared by the reverse transcription reaction of the human placenta and liver MnRNA preparation (Clontech, Palo Alto, Calif., USA) using synthetic Primer 2 and RAV-2 reverse transcriptase. Then the PCR amplification of the targeted cDNA was performed using synthetic Primer 4 (EcoRI linker+sense, position 62;5′-CGCGAATTCTCGAGACTGTAGGCACT-3′, SEQ ID NO: 8) and Primer 2 and pfu DNA polymerase (Stratagene, Lajolla, Calif., USA). PCR was performed using Takara RT-PCR kit in accordance with the instructions of use on the thermal cycler ZYMOREACTOR 11 (ATTO, Tokyo, Japan) with 35 cycles of 94° C. for 30 s, 55° C. for 1 minute, and 75° C. for 8 minutes. Thus amplified cDNA fragments were separated by electrophoresis on 1% agarose gel and the DNA in the desired band was purified using the DNA purification kit QIAEX11(QIAGEN, Hilden, Germany). The purified cDNA fragment was digested with Eco RI and subsequently subcloned into the Eco RI site of an expression vector, namely pTrcHisA (Invitrogen, San Diego, USA). Thus cloned DPD cDNA expressed a protein of about 120 kDa as a fusion protein of the full DPD with histidine tagged protein, which was used in the further screening.

[0118] (B) Screening

[0119] The above obtained recombinant DPD was subjected to electrophoresis on NPG-D520L gel (Pagel, ATTO, Tokyo, Japan) in accordance with Laemmli's methodology, and the protein was blotted onto PVDF membranes, (Immobilon, Millipore, Bedford, Mass., USA) using a semi-dry blotter (ATTO, Tokyo, Japan). The PVDF membranes onto which the DPD protein was blotted were blocked using TBS containing 3% of skim milk, and were washed with TTBS, and subsequently were submitted to the reaction with the culture supernatants of the hybridomas described in Example 1 on Screener Blotter Mini 28 (Sanplatec Corp., Japan) at room temperature for one hour. Then, after washing the PVDF membranes with TTBS, they were reacted with HRP-labeled goat anti-mouse IgG+A+M antibody (KPL) at room temperature for one hour. The membranes were washed with TTBS again and were subjected to a coloring reaction using Konica Immunostaining HRP-1000 (Konica, Tokyo, Japan). The colonies such as e.g. those designated 2B6, 9C7, 5E6, 3A5 and 6H5 which reacted strongly with the recombinant DPD of about 120 kDa were collected as the candidates. As used herein, a monoclonal antibody produced by a particular hybridoma, e.g. hybridoma 2B6, is designated by adding “Mab-” to the head of the name of the hybridoma, for instance Mab-2B6.

[0120] The above candidates were cloned by repeating the limiting dilution method twice or more to establish the hybridoma cell lines (including e.g. 2B6-11-1, 9C7-30-1, 5E6-19-1, 3A5-6-1 and 6H5-42-1). After the first limiting dilution, the specificity of the above monoclonal antibodies, i.e. Mab-2B6-11, Mab-9C7-30, Mab-5E6-19, Mab-3A 5-6 and Mab-6H5-42 were evaluated by Western blotting using the samples containing DPD.

[0121]FIG. 2 shows the results of the Western blotting for monoclonal antibodies produced by hybridoma cell lines 2B6-11, 9C7-30, 3A5-6-1, 5E6-19 and 6H5-42. As it is shown in this Figure, the resulting immunoconjugates with the antibodies and DPD were observed around the position of molecular weight of about 110-120 kDa.

[0122] The subclass of the monoclonal antibodies produced by the above hybridoma cell lines were investigated using Mouse Mono Ab-ID EIA Kit (Zymed, San Francisco, Calif., USA) and were determined as Mab-2B6-11-1 (IgG1, κ), Mab-9C7-30-1 (IgG1, κ), Mab-5E6-19-1 (IgG3, κ), Mab-3A5-6-1 (IgM, κ), Mab-6H542-1 (IgM, κ), respectively. It was confirmed that the above monoclonal antibodies were applicable to a sandwich ELISA for the detection of DPD. However, for the purpose of constructing a more sensitive ELISA system, a further screening was decided to be preferable since the concentration of DPD in tumor tissues was, expected to be lower than in liver and high sensitivity will be desired so as to enable the distinction between a DPD-deficient level and normal level.

[0123] (2-3) Third Screening

[0124] Taking the monoclonal antibody of the hybridoma 3A5-6-1 as a representative, further monoclonal antibodies which recognize the different epitopes from that recognized by the antibody of Mab-3A5-6-1 and which would achieve a higher sensitivity in the detection of the native DPD in tissues than the above mentioned antibodies were screened.

[0125] The monoclonal antibody. Mab-3A5-6-1 was used to coat the wells of the plate using 50 μl/well in the concentration of 10 μg/ml, and after the unbound antibody was removed, the respective wells were blocked using TBS containing 3% of skim milk at room temperature for an hour. After washing with TTBS, the wells were reacted with 50 μl/well of a mouse liver homogenate in the concentration of about 2mg/ml at room temperature for one hour. After washing with TTBS, the wells were reacted with the primary stock of the hybridoma culture supernatants in the amount of 50 μl/well at 37° C. for 1 hour. After washing again with TTBS, the wells were reacted with HRP labeled Rat anti-mouse IgG1 specific monoclonal antibody (Zymed, San Francisco, Calif., USA) at 37° C. for 1 hour. Subsequent to washing with TTBS, the wells were subjected to the color development with TMB microwell peroxidase kit system (KPL), then the reaction was stopped by the addition of 1 M phosphoric acid and the absorption was measured at 450 nm using a microtiter plate reader.

[0126] The 22 wells with strong reaction were determined and the hybridomas of these wells were subjected to further screening in the same manner as described above by substituting the above mouse liver homogenate with the homogenates of human tumor cell lines, HT-3 and MCF-7. The said HT-3 had the DPD activity of 160 pmol/minute/mg protein and was detected as a single band around 110 kDa by Western blotting using rabbit anti-DPD-Peptide 1 or anti-Peptide 2 polyclonal antibody. On the other hand, whilst cell line MCF-7 had a DPD activity of about 1.6 pmol/minute/mg, it was not detected by the similar Western blotting. Thus the inventors selected the hybridomas (designated as 4B9 and 2E2) which reacted strongly with cell line HT-3 but not with cell line MCF-7 These hybridomas 4B9 and 2E2 were further subjected to the limiting dilution method twice or more and the hybridoma clones 4B9-12-1 and 2E2-B3-1-3 (the antibodies of which were determined as IgG1, κ) were established.

[0127] The monoclonal antibodies Mab-4B9-12-1 and Mab-2E2-B3-1-3 were confirmed in their specificity to the solubilized state DPD antigen by the immunoprecipitation.

[0128] (2-4) Purification of Monoclonal Antibodies

[0129] In general, once a hybridoma capable of producing a monoclonal antibody of the present invention is established, the production and purification of the monoclonal antibody can be conducted by any means for the production and purification of monoclonal antibodies known in the art. For example, the production of the monoclonal antibodies can be performed by cultivating the hybridoma cells in an appropriate culture medium, and recovering and purifying the antibodies from the culture. Alternatively the proliferation of the hybridoma cells can be conducted by planting the cells in peritoneal ascites of mice. The production and purification of the monoclonal antibodies are performed by a conventional method, exemplified as follows for specific monoclonal antibodies:

[0130] 1) Mab-4B9-12-1

[0131] The hybridoma cell line 4B9-12-1 was cultured in a serum-free medium (PM 1000 Kit, Eiken, Tokyo, Japan) at the cell concentration of about 5×10⁵/ml. The supernatant of the culture was collected and antibodies (IgG) was purified by applying the supernatant through HiTrap protein G column (Pharmacia, Uppsala, Sweden) as follows.

[0132] HiTrap protein G column was equilibrated with 20 mM phosphate buffer (pH 7.0) then the supernatant preparation was applied to the column. After washing the column with 20 mM phosphate buffered saline, the IgG fractions were eluted by 0.1 M glycine-HCl buffer (pH 3.0). Thus collected elution was neutralized by 1 M Tris-HCl (pH 9.0) and then dialyzed against PBS. The protein determination of the purified antibody fraction using BIO-RAD Dc Protein Assay kit (Biorad, Hercules, Calif., USA; the control was BSA) showed about 4 mg of antibody from 300 ml of the culture supernatant. The subclass of this monoclonal antibody was determined to be IgG1, κ.

[0133] 2) Mab-3A5-6-1

[0134] One week after the injection of 0.5 ml of pristane (Sigma, St. Louis, Mo., USA) intraperitoneally to mice, 5×106 of hybridoma 3A5-6-1 cells were inoculated in abdominal cavity of the animals by injection. After two weeks, the ascites were collected from the animals, centrifuged and filtered through 0.8 μm membrane filter. The purification of antibodies (IgM) was performed by using ImmunoPure IgM Purification Kit (Pierce, Rockford, Ill., USA). To 0.5 ml of ascites, 0.5 ml of ImmunoPure IgM binding buffer was added and the mixture was applied to ImmunoPure Immobilized MBP column. After washing the column with ImmunoPure IgM binding Buffer, the antibodies were eluted with ImmunoPure IgM elution buffer, and the fraction of the antibodies were dialyzed against PBS. The protein determination using BSA as the control revealed that about 2 mg of antibodies (IgM) was obtained from about 0.5 ml of the ascites.

EXAMPLE 3

[0135] ELISA using the monoclonal antibodies of the present invention

[0136] As immunological quantitative assays, one point binding methods and two points binding methods (so called sandwich assay) are well known in the art. It can generally be said that two point binding methods are advantageous in achieving higher accuracy and higher sensitivity. The monoclonal antibodies obtained in the above Example 2 were used to construct sandwich ELISA assay systems as described below:

[0137] (a) Coating of the First Antibody

[0138] A solution of Mab-4B9-12-1 was prepared using PBS (pH 7.4) in the concentration of 10 μg/ml and 50 μl of this solution was added to each of the wells of 96-well immunoplates (Maxisorp, Nunc, Roskilde, Denmark), and the wells were sealed by a membrane sealant and incubated at 4° C. overnight to immobilize the antibody (in this Example, the plates were sealed during incubation).

[0139] After recovering the unbound antibody, the wells were washed with TTBS and then blocked by incubating with TBS containing 3% of skim milk at room temperature for 3 hours.

[0140] (b) Application of samples

[0141] As a standard sample containing DPD, HT-3 xenograft homogenate was prepared in the concentration of 2 mg/mil. A serial dilution of the homogenate was prepared in TBS containing 0.3% skim milk, and 50 μl of the samples were added to the respective wells, and then the immunoplate was incubated at 37° C. for 2 hours.

[0142] (c) Reaction with the second antibody

[0143] After washing the wells with TTBS, the second antibody solution which contained 2 μg/ml of Mab-3A5-6-1 in TBS containing 3% skim milk was added to each well in a volume of 50 μl, and the immunoplate was incubated at 37° C. for 1 hour. By this treatment, an immunoconjugate of [Mab-4B9-12-1]-[DPD]-[Mab-3A5-6-l] in which DPD was sandwiched between the two monoclonal antibodies was produced, when DPD was present in the above samples.

[0144] (d) Labeling

[0145] For the purpose of detecting the conjugate, HRP labeled rat anti-mouse IgM antibody (Zymed, San Francisco, Calif., USA) was used to label the conjugate. This commercially available HRP-labeled antibody was used after diluting 1000 times with TBS containing 3% skim milk.

[0146] The wells of the immunoplate were washed with TTBS and were added with 50 μl of the above HRP-labeled antibody, and the plate was incubated 37° C. for 1 hour.

[0147] (e) Detection

[0148] After washing the wells, the coloring reaction was conducted by using TMB microwell peroxidase kit system (KPL) which contained TMB and H₂O₂ as a substrate developing color in the enzymatic reaction catalyzed by HRP. The substrate solution was added to the respective wells, and after the reaction was stopped by addition of 1 M phosphoric acid, the absorption of the wells were measured by a microplate reader (BioRad, Hercules, Calif., USA) at 450 nm.

[0149] The representative results are summarized in Table 1 below, and the calibration curve obtained by the above ELISA system comprising Mab-4B9-12-1 and Mab-3A5-6-1, is illustrated in FIG. 3. In this Figure, the horizontal axis is for logarithm of the HT-3 activity and the perpendicular axis is for logarithm of optical density (OD) measured at the wave length of 450 nm. As it is shown in FIG. 3, that ELISA system of the present invention enables the determination of the DPD activity over the range from about 2.5 to about 170 pmol/minute/ml. This high sensitivity of the DPD ELISA assay will be useful for determining the DPD level of biological samples from human body. Further the above DPD ELISA will thus enable to determine the DPD level of the samples from deficiency disease known to show rather a low level of DPD. TABLE 1 HT-3 activity* (pmol/minute/ml) OD450** 167.5 1.313 83.75 0.894 41.88 0.548 20.94 0.320 10.47 0.175 5.23 0.105 2.61 0.060

EXAMPLE 4

[0150] Comparison between the results of the ELISA and the DPD activity

[0151] The correlation between the level determined by the present ELISA method which was described in Example 3 and the level of enzymatic activity of DPD was investigated. The samples were breast cancer tissues and adjacent normal tissues which were surgical evulsions. The samples were prepared in the forms of tissue homogenates. Briefly, tumor and normal tissues were first homogenized in 10 mM Tris-HCl buffer (pH 7.4) containing 15 mM NaCl, 1.5 mM MgCl₂ and 50 μM potassium phosphate, and then centrifuged at 105000×g for 90 minutes. The supernatant was dialyzed overnight against 20 mM potassium phosphate buffer (pH 7.4) and 1 mM 2-mercaptoethanol.

[0152] The DPD activity was determined by a TLC plate method, close to that described by Fernandez-Salguero et al., 1995, Biochem. Pharm. 50, 1015-1020, wherein the sum of the 5-FU catabolites, i.e. dihydrofluorouracil, α-fluoro-β-ureidopropionate, and α-fluoro-β-alanine, formed from [6-¹⁴C]5-FU was measured as described above. The ELISA was performed in the same manner as described in Example 3 by using a Scaber xenograft homogenate (105 pmol/minute/mg) as the standard.

[0153] Each sample was assayed both by the above TLC plate method and by ELISA and the data of each sample was plotted on a graph of the vertical axis for the amount of DPD in pmol/minute/mg measured by ELISA and the horizontal axis for DPD activity measured by TLC method as shown in FIG. 4. High correlation between the results of the activity assay and the ELISA of the present invention was confirmed for both tumor tissues and normal tissues.

EXAMPLE 5

[0154] Application of the ELISA of the Invention to Measure the Efficacy of Antitumor Medicaments in the Series of 5-fluorouracil (5-FU) Derivatives. Such as FURTULON

[0155] One of the representatives of the antitumor medicaments in the series of 5-fluorouracil (5-FU) derivatives, namely FURTULON (5′-deoxy-5-fluorouridine (5′-dFUrd)) is a prodrug which is converted into 5-FU by the action of pyrimidine nucleoside phosphorylase (PyNPase), i.e. thymidine phosphorylase in human cells.

[0156] A convenient assay system was devised for evaluating the ratio PyNPase/DPD in tumor tissues. That system comprises a combination of the ELISA system for the-assay of PyNPase decribed by Nishida M. et al., 1996, Biol. Pharm. Bull. 19(11), 1407-1411, and the ELISA system of the invention described in the above Example 3.

[0157] To investigate whether the ratio PyNPase/DPD is a marker for the efficacy of FURTULON, that ratio was determined for a number of tumor tissues already known to be susceptible to FURTULON and a number of tumor tissues already known to be refractory to FURTULON. The cell lines used as representative of the FURTULON-susceptible tissues are the following 9 human tumor xenograft cell lines: Scaber (squamous carcinoma, ATCC HTB-3), ZR-75 (breast carcinoma), MCF-7 (breast adenocarcinoma, ATCC HTB-22), LoVo (colorectal cancer, ATCC CCL-229), MKN45 (gastric cancer), SIHA (squamous carcinoma), ME-180 (epidermal carcinoma), HCT116 (colorectal cancer) and COL0205 (colorectal cancer, ATCC CCL 222). The cell lines used as representative of the FURTULON-refractory tissues are the following 7 xenograft cell lines: SK-OV-3 (ovarian tumor, ATCC HTB-77), MAD-MB-231 (breast carcinoma), HT-29 (colorectal cancer, ATCC HTB-38), T-24 (bladder cancer, ATCC HTB-4), PC-3 (prostate adenocarcinoma), WiDr-1 (colorectal cancer, ATCC CCL-218) and MKN28 (gastric cancer).

[0158] The ratios determined based on the ELISA system of the present invention are plotted in the graph of FIG. 5. As it is shown in that Figure, the FURTULON-susceptible cell lines showed substantially higher PyNPase/DPD ratios than the refractory cell lines.

[0159] This result shows that the PyNPase/DPD ratio in tumor tissues is useful for measuring the efficacy of FURTULON in the treatment of patients suffering from tumor.

EXAMPLE 6

[0160] Immunoprecipitation assay using monoclonal antibodies according to the invention

[0161] A xenograft homogenate of tumor cell line, HT-3 was used as a biological sample which contained DPD. The xenograft homogenate (8.6 mg/ml) was treated through a protein G sepharose 4B column twice to absorb antibodies originating from the host, and was subjected to the following immunoprecipitation assay.

[0162] To the tubes containing 150 μl of HT-3 xenograft homogenate, 5 μg of monoclonal antibodies according to the invention to be tested were added and the tubes were incubated at for 4° C. for 2 hours. Then, each 20 μl of 50% Protein G-Sepharose 4B (Sigma, ST. Louis, MO., USA) was added to the tube and the mixtures were further incubated at 4° C. for 2 hours. After the reaction, the mixtures were centrifuged to separate into bead fractions and supernatants. The collected bead fractions were washed with 20 mM sodium phosphate buffer (pH 7.0) five times, and eluted into 60 μl of 0.1 M glycine-HCl buffer (pH 3.0); the eluates were neutralized with 3 μl of 1 M Tris-HCl (pH 8.0) to obtain the preparation of the immunoprecipitates.

[0163] The samples of the supernatants and the eluates from the bead fractions, hereafter referred as bead eluates, were analyzed by SDS-PAGE and Western blotting.

[0164]FIG. 6 illustrates the results of the immunoprecipitation assay using the monoclonal antibodies of the present invention Mab-2B6-1 1-1, Mab-2E2-B3-1-3, Mab-4B9-12-1 and Mab-9C7-30-1.

[0165] FIGS. 6-1 (a) and (b) show the electrophoretic pattern of SDS-PAGE, where (a) is for the supernatants and (b) is the bead eluates of the immunoprecipitates, the bands being visualized by silver staining (2D-silver stain Daiichi, Daiichi Pure Chemicals, Tokyo, Japan).

[0166]FIG. 6-2 (a), (b) and (c) show a results of Western blotting, where (a) is the result obtained from the supernatant detected using anti DPD-1 polypeptide antibody, (b) is the result from the bead eluates from the immunoprecipitates detected by using anti DPD-1 polypeptide antibody, and (c) show the result from the same bead eluates as (b) in which the monoclonal antibody 3A5-6-1 of the present invention was used for the detection. The respective lanes correspond to the results of the immunoprecipitation assay using the following samples: lane 1: mouse IgG 1; lane 2: 2B6-11-1; lane 3: 2E2-B3-1-3; lane: 4B9-12-1; and lane 5: 9C7-30-1. The lane c in FIG. 6-2 (b) is the run of homogenate of HT-3 as a positive control.

[0167] As shown in FIG. 6-1 (b), the immunoprecipitation was observed as the bands corresponding to about 120 kDa in the cases of the monoclonal antibodies of the present invention, Mab-2E2-B3-1-3 (lane 3), and Mab-4B9-12-1 (lane 4). On the PAGE gel, the bands seen around 50 kDa and 25 kDa correspond to the heavy chain and light chain of the antibodies utilized.

[0168] At the same time, Western blotting was carried out using the supernatant and the bead eluate. Either rabbit anti-DPD peptide-1 antibody or Mab-3A5-6-1 was utilized for the detection of DPD. As it is shown in FIG. 6-1(a), the band corresponding to DPD was not observed in the samples of the supernatant (see lanes 3 and 4), while the single bands around 120 kDa were observed using anti-DPD peptide-1 antibody or Mab-3A5-6-1 in the samples which were eluted from the beads resulted from the immuno precipitation with Mab-4B9-12-1 and Mab-2E2-B3-1-3 as show in FIG. 6-2(b) and (c), which evidenced that the single band observed near 120 kDa on SDS-PAGE corresponded to DPD. Further, the DPD activities in the samples of the bead eluates from the immuno precipitates with Mab-4B9-12-1 and the corresponding supernatant were assayed, and the DPD activity was observed only in the bead eluates from the immunoprecipitates as shown in Table 2 below: TABLE 2 [DPD activity: pmol/minute/ml] HT-3 homogenate /Mab + beads Antibody added Supernatants Bead eluates Mouse IgG1 118.2 <1.41 4B9-12-1 <1.41 85.3

[0169] These results show that the monoclonal antibodies of the present invention, i.e. Mab-4B9-12-1 and Mab-2E2-B3-1-3 recognize the active DPD molecule having the native conformation and that the specificity of these antibodies to DPD is very high as their immunoprecipitates are observed as single bands.

[0170] Moreover, it was confirmed that Mab-3A5-6-1 specifically recognizes the DPD molecule which was also specifically recognized by Mab-4B9-12-1, this ensures the reliability of the sandwich ELISA system using these monoclonal antibodies of the present invention.

[0171] As the skilled person will readily understand, monoclonal antibodies according to the present invention are also useful for the preparation of an affinity column for the purification of DPD.

0 SEQUENCE LISTING <160> NUMBER OF SEQ ID NOS: 8 <210> SEQ ID NO 1 <211> LENGTH: 3951 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 1 gctgtcactt ggctctctgg ctggagcttg aggacgcaag gagggtttgt cactggcaga 60 ctcgagactg taggcactgc catggcccct gtgctcagta aggactcggc ggacatcgag 120 agtatcctgg ctttaaatcc tcgaacacaa actcatgcaa ctctgtgttc cacttcggcc 180 aagaaattag acaagaaaca ttggaaaaga aatcctgata agaactgctt taattgtgag 240 aagctggaga ataattttga tgacatcaag cacacgactc ttggtgagcg aggagctctc 300 cgagaagcaa tgagatgcct gaaatgtgca gatgccccgt gtcagaagag ctgtccaact 360 aatcttgata ttaaatcatt catcacaagt attgcaaaca agaactatta tggagctgct 420 aagatgatat tttctgacaa cccacttggt ctgacttgtg gaatggtatg tccaacctct 480 gatctatgtg taggtggatg caatttatat gccactgaag agggacccat taatattggt 540 ggattgcagc aatttgctac tgaggtattc aaagcaatga gtatcccaca gatcagaaat 600 ccttcgctgc ctcccccaga aaaaatgtct gaagcctatt ctgcaaagat tgctcttttt 660 ggtgctgggc ctgcaagtat aagttgtgct tcctttttgg ctcgattggg gtactctgac 720 atcactatat ttgaaaaaca agaatatgtt ggtggtttaa gtacttctga aattcctcag 780 ttccggctgc cgtatgatgt agtgaatttt gagattgagc taatgaagga ccttggtgta 840 aagataattt gcggtaaaag cctttcagtg aatgaaatga ctcttagcac tttgaaagaa 900 aaaggctaca aagctgcttt cattggaata ggtttgccag aacccaataa agatgccatc 960 ttccaaggcc tgacgcagga ccaggggttt tatacatcca aagacttttt gccacttgta 1020 gccaaaggca gtaaagcagg aatgtgcgcc tgtcactctc cattgccatc gatacgggga 1080 gtcgtgattg tacttggagc tggagacact gccttcgact gtgcaacatc tgctctacgt 1140 tgtggagctc gccgagtgtt catcgtcttc agaaaaggct ttgttaatat aagagctgtc 1200 cctgaggaga tggagcttgc taaggaagaa aagtgtgaat ttctgccatt cctgtcccca 1260 cggaaggtta tagtaaaagg tgggagaatt gttgctatgc agtttgttcg gacagagcaa 1320 gatgaaactg gaaaatggaa tgaagatgaa gatcagatgg tccatctgaa agccgatgtg 1380 gtcatcagtg cctttggttc agttctgagt gatcctaaag taaaagaagc cttgagccct 1440 ataaaattta acagatgggg tctcccagaa gtagatccag aaactatgca aactagtgaa 1500 gcatgggtat ttgcaggtgg tgatgtcgtt ggtttggcta acactacagt ggaatcggtg 1560 aatgatggaa agcaagcttc ttggtacatt cacaaatacg tacagtcaca atatggagct 1620 tccgtttctg ccaagcctga actacccctc ttttacactc ctattgatct ggtggacatt 1680 agtgtagaaa tggccggatt gaagtttata aatccttttg gtcttgctag cgcaactcca 1740 gccaccagca catcaatgat tcgaagagct tttgaagctg gatggggttt tgccctcacc 1800 aaaactttct ctcttgataa ggacattgtg acaaatgttt cccccagaat catccgggga 1860 accacctctg gccccatgta tggccctgga caaagctcct ttctgaatat tgagctcatc 1920 agtgagaaaa cggctgcata ttggtgtcaa agtgtcactg aactaaaggc tgacttccca 1980 gacaacattg tgattgctag cattatgtgc agttacaata aaaatgactg gacggaactt 2040 gccaagaagt ctgaggattc tggagcagat gccctggagt taaatttatc atgtccacat 2100 ggcatgggag aaagaggaat gggcctggcc tgtgggcagg atccagagct ggtgcggaac 2160 atctgccgct gggttaggca agctgttcag attccttttt ttgccaagct gaccccaaat 2220 gtcactgata ttgtgagcat cgcaagagct gcaaaggaag gtggtgccaa tggcgttaca 2280 gccaccaaca ctgtctcagg tctgatggga ttaaaatctg atggcacacc ttggccagca 2340 gtggggattg caaagcgaac tacatatgga ggagtgtctg ggacagcaat cagacctatt 2400 gctttgagag ctgtgacctc cattgctcgt gctctgcctg gatttcccat tttggctact 2460 ggtggaattg actctgctga aagtggtctt cagtttctcc atagtggtgc ttccgtcctc 2520 caggtatgca gtgccattca gaatcaggat ttcactgtga tcgaagacta ctgcactggc 2580 ctcaaagccc tgctttatct gaaaagcatt gaagaactac aagactggga tggacagagt 2640 ccagctactg tgagtcacca gaaagggaaa ccagttccac gtatagctga actcatggac 2700 aagaaactgc caagttttgg accttatctg gaacagcgca agaaaatcat agcagaaaac 2760 aagattagac tgaaagaaca aaatgtagct ttttcaccac ttaagagaag ctgttttatc 2820 cccaaaaggc ctattcctac catcaaggat gtaataggaa aagcactgca gtaccttgga 2880 acatttggtg aattgagcaa cgtagagcaa gttgtggcta tgattgatga agaaatgtgt 2940 atcaactgtg gtaaatgcta catgacctgt aatgattctg gctaccaggc tatacagttt 3000 gatccagaaa cccacctgcc caccataacc gacacttgta caggctgtac tctgtgtctc 3060 agtgtttgcc ctattgtcga ctgcatcaaa atggtttcca ggacaacacc ttatgaacca 3120 aagagaggcg tacccttatc tgtgaatccg gtgtgttaag gtgatttgtg aaacagttgc 3180 tgtgaacttt catgtcacct acatatgctg atctcttaaa atcatgatcc ttgtgttcag 3240 ctctttccaa attaaaacaa atatacattt tctaaataaa aatatgtaat ttcaaaatac 3300 atttgtaagt gtaaaaaatg tctcatgtca atgaccattc aattagtggc ataaaataga 3360 ataattcttt tctgaggata gtagttaaat aactgtgtgg cagttaattg gatgttcact 3420 gccagttgtc ttatgtgaaa aattaacttt ttgtgtggca attagtgtga cagtttccaa 3480 attgccctat gctgtgctcc atatttgatt tctaattgta agtgaaatta agcattttga 3540 aacaaagtac tctttaacat acaagaaaat gtatccaagg aaacatttta tcaataaaaa 3600 ttacctttaa ttttaatgct gtttctaaga aaatgtagtt agctccataa agtacaaatg 3660 aagaaagtca aaaattattt gctatggcag gataagaaag cctaaaattg agtttgtgga 3720 ctttattaag taaaatcccc ttcgctgaaa ttgcttattt ttggtgttgg atagaggata 3780 gggagaatat ttactaacta aataccattc actactcatg cgtgagatgg gtgtacaaac 3840 tcatcctctt ttaatggcat ttctctttaa actatgttcc taaccaaatg agatgatagg 3900 atagatcctg gttaccactc ttttactgtg cacatatggg ccccggaatt c 3951 <210> SEQ ID NO 2 <211> LENGTH: 1025 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 2 Met Ala Pro Val Leu Ser Lys Asp Ser Ala Asp Ile Glu Ser Ile Leu 1 5 10 15 Ala Leu Asn Pro Arg Thr Gln Thr His Ala Thr Leu Cys Ser Thr Ser 20 25 30 Ala Lys Lys Leu Asp Lys Lys His Trp Lys Arg Asn Pro Asp Lys Asn 35 40 45 Cys Phe Asn Cys Glu Lys Leu Glu Asn Asn Phe Asp Asp Ile Lys His 50 55 60 Thr Thr Leu Gly Glu Arg Gly Ala Leu Arg Glu Ala Met Arg Cys Leu 65 70 75 80 Lys Cys Ala Asp Ala Pro Cys Gln Lys Ser Cys Pro Thr Asn Leu Asp 85 90 95 Ile Lys Ser Phe Ile Thr Ser Ile Ala Asn Lys Asn Tyr Tyr Gly Ala 100 105 110 Ala Lys Met Ile Phe Ser Asp Asn Pro Leu Gly Leu Thr Cys Gly Met 115 120 125 Val Cys Pro Thr Ser Asp Leu Cys Val Gly Gly Cys Asn Leu Tyr Ala 130 135 140 Thr Glu Glu Gly Pro Ile Asn Ile Gly Gly Leu Gln Gln Phe Ala Thr 145 150 155 160 Glu Val Phe Lys Ala Met Ser Ile Pro Gln Ile Arg Asn Pro Ser Leu 165 170 175 Pro Pro Pro Glu Lys Met Ser Glu Ala Tyr Ser Ala Lys Ile Ala Leu 180 185 190 Phe Gly Ala Gly Pro Ala Ser Ile Ser Cys Ala Ser Phe Leu Ala Arg 195 200 205 Leu Gly Tyr Ser Asp Ile Thr Ile Phe Glu Lys Gln Glu Tyr Val Gly 210 215 220 Gly Leu Ser Thr Ser Glu Ile Pro Gln Phe Arg Leu Pro Tyr Asp Val 225 230 235 240 Val Asn Phe Glu Ile Glu Leu Met Lys Asp Leu Gly Val Lys Ile Ile 245 250 255 Cys Gly Lys Ser Leu Ser Val Asn Glu Met Thr Leu Ser Thr Leu Lys 260 265 270 Glu Lys Gly Tyr Lys Ala Ala Phe Ile Gly Ile Gly Leu Pro Glu Pro 275 280 285 Asn Lys Asp Ala Ile Phe Gln Gly Leu Thr Gln Asp Gln Gly Phe Tyr 290 295 300 Thr Ser Lys Asp Phe Leu Pro Leu Val Ala Lys Gly Ser Lys Ala Gly 305 310 315 320 Met Cys Ala Cys His Ser Pro Leu Pro Ser Ile Arg Gly Val Val Ile 325 330 335 Val Leu Gly Ala Gly Asp Thr Ala Phe Asp Cys Ala Thr Ser Ala Leu 340 345 350 Arg Cys Gly Ala Arg Arg Val Phe Ile Val Phe Arg Lys Gly Phe Val 355 360 365 Asn Ile Arg Ala Val Pro Glu Glu Met Glu Leu Ala Lys Glu Glu Lys 370 375 380 Cys Glu Phe Leu Pro Phe Leu Ser Pro Arg Lys Val Ile Val Lys Gly 385 390 395 400 Gly Arg Ile Val Ala Met Gln Phe Val Arg Thr Glu Gln Asp Glu Thr 405 410 415 Gly Lys Trp Asn Glu Asp Glu Asp Gln Met Val His Leu Lys Ala Asp 420 425 430 Val Val Ile Ser Ala Phe Gly Ser Val Leu Ser Asp Pro Lys Val Lys 435 440 445 Glu Ala Leu Ser Pro Ile Lys Phe Asn Arg Trp Gly Leu Pro Glu Val 450 455 460 Asp Pro Glu Thr Met Gln Thr Ser Glu Ala Trp Val Phe Ala Gly Gly 465 470 475 480 Asp Val Val Gly Leu Ala Asn Thr Thr Val Glu Ser Val Asn Asp Gly 485 490 495 Lys Gln Ala Ser Trp Tyr Ile His Lys Tyr Val Gln Ser Gln Tyr Gly 500 505 510 Ala Ser Val Ser Ala Lys Pro Glu Leu Pro Leu Phe Tyr Thr Pro Ile 515 520 525 Asp Leu Val Asp Ile Ser Val Glu Met Ala Gly Leu Lys Phe Ile Asn 530 535 540 Pro Phe Gly Leu Ala Ser Ala Thr Pro Ala Thr Ser Thr Ser Met Ile 545 550 555 560 Arg Arg Ala Phe Glu Ala Gly Trp Gly Phe Ala Leu Thr Lys Thr Phe 565 570 575 Ser Leu Asp Lys Asp Ile Val Thr Asn Val Ser Pro Arg Ile Ile Arg 580 585 590 Gly Thr Thr Ser Gly Pro Met Tyr Gly Pro Gly Gln Ser Ser Phe Leu 595 600 605 Asn Ile Glu Leu Ile Ser Glu Lys Thr Ala Ala Tyr Trp Cys Gln Ser 610 615 620 Val Thr Glu Leu Lys Ala Asp Phe Pro Asp Asn Ile Val Ile Ala Ser 625 630 635 640 Ile Met Cys Ser Tyr Asn Lys Asn Asp Trp Thr Glu Leu Ala Lys Lys 645 650 655 Ser Glu Asp Ser Gly Ala Asp Ala Leu Glu Leu Asn Leu Ser Cys Pro 660 665 670 His Gly Met Gly Glu Arg Gly Met Gly Leu Ala Cys Gly Gln Asp Pro 675 680 685 Glu Leu Val Arg Asn Ile Cys Arg Trp Val Arg Gln Ala Val Gln Ile 690 695 700 Pro Phe Phe Ala Lys Leu Thr Pro Asn Val Thr Asp Ile Val Ser Ile 705 710 715 720 Ala Arg Ala Ala Lys Glu Gly Gly Ala Asn Gly Val Thr Ala Thr Asn 725 730 735 Thr Val Ser Gly Leu Met Gly Leu Lys Ser Asp Gly Thr Pro Trp Pro 740 745 750 Ala Val Gly Ile Ala Lys Arg Thr Thr Tyr Gly Gly Val Ser Gly Thr 755 760 765 Ala Ile Arg Pro Ile Ala Leu Arg Ala Val Thr Ser Ile Ala Arg Ala 770 775 780 Leu Pro Gly Phe Pro Ile Leu Ala Thr Gly Gly Ile Asp Ser Ala Glu 785 790 795 800 Ser Gly Leu Gln Phe Leu His Ser Gly Ala Ser Val Leu Gln Val Cys 805 810 815 Ser Ala Ile Gln Asn Gln Asp Phe Thr Val Ile Glu Asp Tyr Cys Thr 820 825 830 Gly Leu Lys Ala Leu Leu Tyr Leu Lys Ser Ile Glu Glu Leu Gln Asp 835 840 845 Trp Asp Gly Gln Ser Pro Ala Thr Val Ser His Gln Lys Gly Lys Pro 850 855 860 Val Pro Arg Ile Ala Glu Leu Met Asp Lys Lys Leu Pro Ser Phe Gly 865 870 875 880 Pro Tyr Leu Glu Gln Arg Lys Lys Ile Ile Ala Glu Asn Lys Ile Arg 885 890 895 Leu Lys Glu Gln Asn Val Ala Phe Ser Pro Leu Lys Arg Ser Cys Phe 900 905 910 Ile Pro Lys Arg Pro Ile Pro Thr Ile Lys Asp Val Ile Gly Lys Ala 915 920 925 Leu Gln Tyr Leu Gly Thr Phe Gly Glu Leu Ser Asn Val Glu Gln Val 930 935 940 Val Ala Met Ile Asp Glu Glu Met Cys Ile Asn Cys Gly Lys Cys Tyr 945 950 955 960 Met Thr Cys Asn Asp Ser Gly Tyr Gln Ala Ile Gln Phe Asp Pro Glu 965 970 975 Thr His Leu Pro Thr Ile Thr Asp Thr Cys Thr Gly Cys Thr Leu Cys 980 985 990 Leu Ser Val Cys Pro Ile Val Asp Cys Ile Lys Met Val Ser Arg Thr 995 1000 1005 Thr Pro Tyr Glu Pro Lys Arg Gly Val Pro Leu Ser Val Asn Pro Val 1010 1015 1020 Cys 1025 <210> SEQ ID NO 3 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Cloned segment of DPD gene, corresponding to nucleotides 1770-1785 of SEQ ID No: 1, with Eco RI Linker at 5′ end <400> SEQUENCE: 3 cgcgaattct tttgaagctg gatgg 25 <210> SEQ ID NO 4 <211> LENGTH: 26 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: 26mer sequence corresponding to negative strand complementary to 3148- 3164 of SEQ ID NO: 1, with Eco RI linker at 5′ end <400> SEQUENCE: 4 cgcgaattct caccttaaca caccgg 26 <210> SEQ ID NO 5 <211> LENGTH: 16 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: 16mer negative strand complementary to nucleotides 3495-3510 of SEQ ID No:1 <400> SEQUENCE: 5 aatcaaatat ggagca 16 <210> SEQ ID NO 6 <211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic sequence corresponding to residues 52-69 of SEQ ID No: 2 <400> SEQUENCE: 6 Cys Glu Lys Leu Glu Asn Asn Phe Asp Asp Ile Lys His Thr Thr Leu 1 5 10 15 Gly Glu <210> SEQ ID NO 7 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthesized based on sequence described in SEQ ID No: 2 and corresponding to 660-679 <400> SEQUENCE: 7 Ser Gly Ala Asp Ala Leu Glu Leu Asn Leu Ser Cys Pro His Gly Met 1 5 10 15 Gly Glu Arg Gly 20 <210> SEQ ID NO 8 <211> LENGTH: 26 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Eco RI linker attached to 5′ end of cloned sequence corresponding to nucleotides 62-78 of SEQ ID No: 1 <400> SEQUENCE: 8 cgcgaattct cgagactgta ggcact 26 

1. An immunoassay for detecting or determining the amount of dihydropyrimidine dehydrogenase in a biological sample which comprises: contacting a monoclonal antibody that specifically binds to dihydropyrimidine dehydrogenase with a biological sample suspected of having dihydropyrimidine dehydrogenase therein, wherein the first monoclonal antibody is produced by a hybridoma cell line selected from the group consisting of hybridoma cell lines 3A5-6-1 (FERM BP-6015), 4B9-12-1 (FERM BP-6016) and 2E2-B3-1-3 (FERM BP-6014); allowing the first monoclonal antibody to specifically bind to any dihydropyrimidine dehydrogenase present in the sample to form an immunoconjugate; and, qualitatively or quantitatively detecting the presence or absence of the immunoconjugate wherein the presence of the immunoconjugate is indicative of the presence of dihydropyrimidine dehydrogenase in the biological sample.
 2. The immunoassay according to claim 1 wherein the presence or absence of the immunoconjugate is detected with the aid of a label.
 3. The immunoassay according to claim 1 wherein the monoclonal antibody is adsorbed on a solid support.
 4. An immunoassay for detecting or determining the amount of dihydropyrimidine dehydrogenase in a biological sample which comprises: contacting a monoclonal antibody that specifically binds to dihydropyrimidine dehydrogenase with a biological sample suspected of having dihydropyrimidine dehydrogenase therein, wherein the mono clonal antibody crossreacts with a monoclonal antibody produced by a hybridoma cell line selected from the group consisting of hybridoma cell lines 3A5-6-1 (FERM BP-6015), 4B9-12-1 (FERM BP-6016) and 2E2-B3-1-3 (FERM BP-6014); allowing the crossreacting monoclonal antibody to specifically bind to any dihydropyrimidine dehydrogenase present in the sample to form an immunoconjugate; and, qualitatively or quantitatively detecting the presence or absence of the immunoconjugate wherein the presence of the immunoconjugate is indicative of the presence of dihydropyrimidine dehydrogenase in the biological sample.
 5. The immunoassay according to claim 4 wherein the presence or absence of the immunoconjugate is detected with the aid of a label.
 6. The immunoassay according to claim 4 wherein the crossreacting monoclonal antibody is adsorbed on a solid support.
 7. An immunoassay for detecting or determining the amount of dihydropyrimidine dehydrogenase in a biological sample which comprises: contacting a solid support having adsorbed thereon a monoclonal antibody that specifically binds to dihydropyrimidine dehydrogenase with a biological sample suspected of having dihydropyrimidine dehydrogenase present therein, wherein the monoclonal antibody comprises a first monoclonal antibody produced by a hybridoma cell line selected from the group consisting of hybridoma cell lines 3A5-6-1 (FERM BP-6015), 4B9-12-1 (FERM BP-6016) and 2E2-B3-1-3 (FERM BP-6014); allowing the first monoclonal antibody to specifically bind to any dihydropyrimidine dehydrogenase in the sample, thereby forming an immunoconjugate on the solid support; and, qualitatively or quantitatively detecting the presence or absence of the immunoconjugate on the solid support wherein the presence of the immunoconjugate on the solid support is indicative of the presence of dihydropyrimidine dehydrogenase in the biological sample.
 8. An immunoassay according to claim 7 wherein the presence or absence of the immunoconjugate on the solid support is detected by: adding a second antibody that specifically binds to dihydropyrimidine dehydrogenase; allowing the second antibody to specifically bind with any dihydropyrimidine dehydrogenase present in the immunoconjugate on the solid support to form a sandwiched conjugate; and, qualitatively or quantitatively detecting the presence or absence of the sandwiched conjugate with the aid of a label wherein the presence of the sandwiched complex is indicative of the presence of the immunoconjugate on the solid support.
 9. An immunoassay according to claim 8 wherein the present or absence of the sandwiched conjugate is detected by: adding a third antibody that specifically binds to the second antibody, wherein the third antibody is conjugated with a label thereby forming a labeled complex comprising the label bound to the solid support; and, determining the presence or the absence of the label bound to the solid support in the labeled complex.
 10. An immunoassay according to claim 8 wherein the second antibody is a monoclonal antibody different from the first monoclonal antibody and wherein the second monoclonal antibody is produced by a hybridoma cell line selected from the group consisting of hybridoma cell lines 3A5-6-1 (FERM BP-6015), 4B9-12-1 (FERM BP-6016) and 2E2-B3-1-3 (FERM BP-6014).
 11. An immunoassay according to claim 10 wherein the first monoclonal antibody is produced from the hybridoma cell line 3A5-6-1 (FERM BP-6015) and the second monoclonal antibody is produced from the hybridoma cell line 4B9-12-1 (FERM BP-6016).
 12. An immunoassay according to claim 10 wherein the first monoclonal antibody is produced from the hybridoma cell line 4B9-12-1 (FERM BP-6016) and the second monoclonal antibody is produced from the hybridoma cell line 3A5-6-1 (FERM BP-6015).
 13. An immunoassay according to claim 8 wherein the second antibody is conjugated with the label.
 14. An immunoassay according to claim 13 wherein the label is selected from the group consisting of an enzyme label, a biotin label, a radioisotope label and a latex particle label.
 15. An immunoassay according to claim 9 wherein the label is selected from the group consisting of an enzyme label, a biotin label and a radioisotope label.
 16. An immunoassay according to claim 15 wherein the label is a radioisotope label.
 17. An immunoassay for detecting or determining the amount of dihydropyrimidine dehydrogenase in a biological sample which comprises: contacting a solid support having adsorbed thereon a monoclonal antibody that specifically binds to dihydropyrimidine dehydrogenase with a biological sample suspected of having dihydropyrimidine dehydrogenase present therein, wherein the monoclonal antibody comprises a first monoclonal antibody that crossreacts with a monoclonal antibody produced by a hybridoma cell line selected from the group consisting of hybridoma cell lines 3A5-6-1 (FERM BP-6015), 4B9-12-1 (FERM BP-6016) and 2E2-B3-1-3 (FERM BP-6014); allowing the first monoclonal antibody to specifically bind to any dihydropyrimidine dehydrogenase in the sample, thereby forming an immunoconjugate on the solid support; and, qualitatively or quantitatively detecting the presence or absence of the immunoconjugate on the solid support wherein the presence of the immunoconjugate on the solid support is indicative of the presence of dihydropyrimidine dehydrogenase in the biological sample.
 18. An immunoassay according to claim 17 wherein the presence or absence of the immunoconjugate on the solid support is detected by: adding a second antibody that specifically binds to dihydropyrimidine dehydrogenase; allowing the second antibody to specifically bind with any dihydropyrimidine dehydrogenase present in the immunoconjugate on the solid support to form a sandwiched conjugate; and, qualitatively or quantitatively detecting the presence or absence of the sandwiched conjugate with the aid of a label wherein the presence of the sandwiched complex is indicative of the presence of the immunoconjugate on the solid support.
 19. An immunoassay according to claim 18 wherein the presence or absence of the sandwiched conjugate is detected by: adding a third antibody that specifically binds to the second antibody, wherein the third antibody is conjugated with a label thereby forming a labeled complex comprising the label bound to the solid support; and, determining the presence or the absence of the label bound to the solid support in the labeled complex.
 20. An immunoassay according to claim 18 wherein the second antibody is a monoclonal antibody different from the first monoclonal antibody and wherein the second monoclonal antibody is produced by a hybridoma cell line selected from the group consisting of hybridoma cell lines 3A5-6-1 (FERM BP-6015), 4B9-12-1 (FERM BP-6016) and 2E2-B3-1-3 (FERM BP-6014).
 21. An immunoassay according to claim 20 wherein the first monoclonal antibody crossreacts with a monoclonal antibody produced from the hybridoma cell line 3A5-6-1 (FERM BP-6015) and the second monoclonal antibody is produced from the hybridoma cell line 4B9-12-1 (FERM BP-6016).
 22. An immunoassay according to claim 20 wherein the first monoclonal antibody crossreacts with a monoclonal antibody produced from the hybridoma cell line 4B9-12-1 (FERM BP-6016) and the second monoclonal antibody is produced from the hybridoma cell line 3A5-6-1 (FERM BP-6015).
 23. An immunoassay according to claim 18 wherein the second antibody is a monoclonal antibody different from the first monoclonal antibody and wherein the second monoclonal antibody crossreacts with a monclonal antibody produced by a hybridoma cell line selected from the group consisting of hybridoma cell lines 3A5-6-1 (FERM BP-6015), 4B9-12-1 (FERM BP-6016) and 2E2-B3-1-3 (FERM BP-6014).
 24. An immunoassay according to claim 23 wherein the first monoclonal antibody crossreacts with a monclonal antibody produced from the hybridoma cell line 3A5-6-1 (FERM BP-6015) and the second monoclonal antibody crossreacts with a monoclonal antibody produced from the hybridoma cell line 4B9-12-1 (FERM BP-6016).
 25. An immunoassay according to claim 23 wherein the first monoclonal antibody crossreacts with a monoclonal antibody produced from the hybridoma cell line 4B9-12-1 (FERM BP-6016) and the second monoclonal antibody crossreacts with a monoclonal antibody produced from the hybridoma cell line 3A5-6-1 (FERM BP-6015).
 26. An immunoassay according to claim 18 wherein the second antibody is conjugated with the label.
 27. An immunoassay according to claim 26 wherein the label is selected from the group consisting of an enzyme label, a biotin label, a radioisotope label and a latex particle label.
 28. An immunoassay according to claim 19 wherein the label is selected from the group consisting of an enzyme label, a biotin label and a radioisotope label.
 29. An immunoassay according to claim 28 wherein the label is a radioisotope.
 30. A method for detecting or determining the amount of dihydropyrimidine dehydrogenase enzymatic activity in a biological sample containing dihydropyrimidine dehydrogenase which comprises: immobilizing on the surface of a suitable container a monoclonal antibody that specifically binds to dihydropyrimidine dehydrogenase, wherein the monoclonal antibody is produced by a hybridoma cell line selected from the group consisting of hybridoma cell lines 3A5-6-1 (FERM BP-6015), 4B9-12-1 (FERM BP-6016) and 2E2-B3-1-3 (FERM BP-6014); contacting the monoclonal antibody with a biological sample suspected of having dihydropyrimidine dehydrogenase therein; allowing the monoclonal antibody to specifically bind to any dihydropyrimidine dehydrogenase in the sample, thereby forming an immunoconjugate and capturing the dihydropyrimidine dehydrogenase on the surface; contacting the captured dihydropyrimidine dehydrogenase with a dihydropyrimidine dehydrogenase substrate; allowing the captured dihydropyrimidine dehydrogenase to react with the dihydropyrimidine dehydrogenase substrate thereby forming an enzymatic product; and, qualitatively or quantitatively detecting the presence or absence of the enzymatic product wherein the presence of the enzymatic product is indicative of dihydropyrimidine dehydrogenase enzymatic activity.
 31. A method for detecting or determining the amount of dihydropyrimidine dehydrogenase enzymatic activity in a biological sample containing dihydropyrimidine dehydrogenase which comprises: immobilizing on the surface of a suitable container a monoclonal antibody that specifically binds to dihydropyrimidine dehydrogenase, wherein the monoclonal antibody crossreacts with a monoclonal antibody produced by a hybridoma cell line selected from the group consisting of hybridoma cell lines 3A5-6-1 (FERM BP-6015), 4B9-12-1 (FERM BP-6016) and 2E2-B3-1-3 (FERM BP-6014); contacting the crossreacting monoclonal antibody with a biological sample suspected of having dihydropyrimidine dehydrogenase therein; allowing the crossreacting monoclonal antibody to specifically bind to any dihydropyrimidine dehydrogenase in the sample, thereby forming an immunoconjugate and capturing the dihydropyrimidine dehydrogenase on the surface; contacting the captured dihydropyrimidine dehydrogenase with a dihydropyrimidine dehydrogenase substrate; allowing the captured dihydropyrimidine dehydrogenase to react with the dihydropyrimidine dehydrogenase substrate thereby forming an enzymatic product; and, qualitatively or quantitatively detecting the presence or absence of the enzymatic product wherein the presence of the enzymatic product is indicative of dihydropyrimidine dehydrogenase enzymatic activity.
 32. A method for determining the DPD deficiency state of a patient which comprises: treating a biological sample from the patient with a monoclonal antibody comprising a first produced by a hybridoma cell line selected from the group consisting of hybridoma cell lines 3A5-6-1 (FERM BP-6015), 4B9-12-1 (FERM BP-6016) and 2E2-B3-1-3 (FERM BP-6014) to form an immunoconjugate; and, quantitatively detecting the immunoconjugate of the first monoclonal antibody and dihydropyrimidine dehydrogenase.
 33. The method of claim 32 wherein the immunoconjugate is detected with the aid of a label.
 34. The method of claim 32 wherein the first monoclonal antibody is adsorbed to a solid support and the immunoconjugate is formed on the solid support.
 35. The method of claim 34 wherein the presence or absence of the immunoconjugate on the solid support is detected by: adding a second antibody that specifically binds to dihydropyrimidine dehydrogenase; allowing the second antibody to specifically bind with any dihydropyrimidine dehydrogenase present in the immunoconjugate on the solid support to form a sandwiched conjugate; and, qualitatively or quantitatively detecting the presence or absence of the sandwiched conjugate with the aid of a label wherein the presence of the sandwiched complex is indicative of the presence of the immunoconjugate on the solid support.
 36. The method of claim 35 wherein the presence or absence of the sandwiched conjugate is detected by: adding a third antibody that specifically binds to the second antibody, wherein the third antibody is conjugated with a label thereby forming a labeled complex comprising the label bound to the solid support; and, determining the presence or the absence of the label bound to the solid support in the labeled complex.
 37. The method of claim 35 wherein the second antibody is a monoclonal antibody different from the first monoclonal antibody and wherein the second monoclonal antibody is produced by a hybridoma cell line selected from the group consisting of hybridoma cell lines 3A5-6-1 (FERM BP-6015), 4B9-12-1 (FERM BP-6016) and 2E2-B3-1-3 TERM BP-6014).
 38. The method of claim 37 wherein the first monoclonal antibody is produced from the hybridoma cell line 3A5-6-1 (FERM BP-6015) and the second monoclonal antibody is produced from the hybridoma cell line 4B9-12-1 (FERM BP-6016).
 39. The method of claim 37 wherein the first monoclonal antibody is produced from the hybridoma cell line 4B9-12-1 (FERM BP-6016) and the second monoclonal antibody is produced from the hybridoma cell line 3A5-6-1 (FERM BP-6015).
 40. for the determining the DPD deficiency state of a patient which comprises: treating a biological sample from the patient with a monoclonal antibody comprising a first monoclonal antibody that crossreacts with a monoclonal antibody that cross reacts with an antibody produced by a hybridoma cell line selected from the group consisting of hybridoma cell lines 3A5-6-1 (FERM BP-6015),4B9-12-1 (FERM BP-6016) and 2E2-B3-1-3 (FERM BP-6014) to form an immunoconjugate; and, quantitatively detecting the immunoconjugate of the first monoclonal antibody and dihydropyrimidine dehydrogenase.
 41. The method of claim 40 wherein the immunoconjugate is detected with the aid of a label.
 42. The method of claim 40 wherein the first monoclonal antibody is adsorbed to a solid support and the immunoconjugate is formed on the solid support.
 43. The method of claim 42 wherein the presence or absence of the immunoconjugate on the solid support is detected by: adding a second antibody that specifically binds to dihydropyrimidine dehydrogenase; allowing the second antibody to specifically bind with any dihydropyrimidine dehydrogenase present in the immunoconjugate on the solid support to form a sandwiched conjugate; and, qualitatively or quantitatively detecting the presence or absence of the sandwiched conjugate with the aid of a label wherein the presence of the sandwiched complex is indicative of the presence of the immunoconjugate on the solid support.
 44. The method of claim 43 wherein the presence or absence of the sandwiched conjugate is detected by: adding a third antibody that specifically binds to the second antibody, wherein the third antibody is conjugated with a label thereby forming a labeled complex comprising the label bound to the solid support; and, determining the presence or the absence of the label bound to the solid support in the labeled complex.
 45. The method of claim 43 wherein the second antibody is a monoclonal antibody different from the first monoclonal antibody and wherein the second monoclonal antibody is produced by a hybridoma cell line selected from the group consisting of hybridoma cell lines 3A5-6-1 (FERM BP-6015),4B9-12-1 (FERM BP-6016) and 2E2-B3-1-3 (FERM BP-6014).
 46. The method of claim 45 wherein the first antibody crossreacts with an antibody produced from the hybridoma cell line 3A5-6-1 (FERM BP-6015) and the second monoclonal antibody is produced from the hybridoma cell line 4B9-12-1 (FERM BP-6016).
 47. The method of claim 45 wherein the first monoclonal antibody crossreacts with an antibody produced from the hybridoma cell line 4B9-12-1 (FERM BP-6016) and the second monoclonal antibody is produced from the hybridoma cell line 3A5-6-1 (FERM BP-6015).
 48. The method of claim 45 wherein the first monoclonal antibody crossreacts with an antibody produced from the hybridoma cell line 3A5-6-1 (FERM BP-6015) and the second monoclonal antibody is one which crossreacts with an antibody produced from the hybridoma cell line 4B9-12-1 (FERM BP-6016).
 49. The method of claim 45 wherein the first monoclonal antibody crossreacts with a monoclonal antibody produced from the hybridoma cell line 4B9-12-1 (FERM BP-6016) and the second monoclonal antibody is one which crossreacts with a monoclonal antibody produced from the hybridoma cell line 3A5-6-1 (FERM BP-6015).
 50. A method for estimating the susceptibility of patients suffering from cancer to treatment with antitumor medicaments in the series of 5-fluorouracil (5-FU) derivatives, which comprises: treating a biological sample from the patient with a monoclonal antibody comprising a first monoclonal antibody produced by a hybridoma cell line selected from the group consisting of hybridoma cell lines 3A5-6-1 (FERM BP-6015), 4B9-12-1 TERM BP-6016) and 2E2-B3-1-3 (FERM BP-6014); to form an immunoconjugate; and, quantitatively detecting the immunoconjugate of the first monoclonal antibody and dihydropyrimidine dehydrogenase, so as to determine the level of dihydropyrimidine dehydrogenase in the biological sample from the patient to obtain a measure of susceptibility.
 51. The method of claim 50 wherein the immunoconjugate is detected with the aid of a label.
 52. The method of claim 50 wherein the first monoclonal antibody is adsorbed to a solid support and the immunoconjugate is formed on the solid support.
 53. The method of claim 52 wherein the presence or absence of the immunoconjugate on the solid support is detected by: adding a second antibody that specifically binds to dihydropyrimidine dehydrogenase; allowing the second antibody to specifically bind with any dihydropyrimidine dehydrogenase present in the immunoconjugate on the solid support to form a sandwiched conjugate; and, qualitatively or quantitatively detecting the presence or absence of the sandwiched conjugate with the aid of a label wherein the presence of the sandwiched complex is indicative of the presence of the immunoconjugate on the solid support.
 54. The method of claim 53 wherein the presence or absence of the sandwiched conjugate is detected by: adding a third antibody that specifically binds to the second antibody, wherein the third antibody is conjugated with a label thereby forming a labeled complex comprising the label bound to the solid support; and, determining the presence or the absence of the label bound to the solid support in the labeled complex.
 55. The method of claim 53 wherein the second antibody is a monoclonal antibody different from the first monoclonal antibody and wherein the second monoclonal antibody is produced by a hybridoma cell line selected from the group consisting of hybridoma cell lines 3A5-6-1 (FERM BP-6015), 4B9-12-1 (FERM BP-6016) and 2E2-B3-1-3 (FERM BP-6014).
 56. The method of claim 55 wherein the first monoclonal antibody is produced from the hybridoma cell line 3A5-6-1 (FERM BP-6015) and the second monoclonal antibody is produced from the hybridoma cell line 4B9-12-1 (FERM BP-6016).
 57. The method of claim 55 wherein the first monoclonal antibody is produced from the hybridoma cell line 4B9-12-1 (FERM BP-6016) and the second monoclonal antibody is produced from the hybridoma cell line 3A5-6-1 (FERM BP-6015).
 58. A method for estimating the susceptibility of patients suffering from cancer to a treatment with antitumor medicaments in the series of 5-fluorouracil (5-FU) derivatives, which comprises: treating a biological sample from the patient with a monoclonal antibody comprising a first monoclonal antibody that crossreacts with a monoclonal antibody produced by a hybridoma cell line selected from the group consisting of hybridoma cell lines 3A5-6-1 (FERM BP-6015), 4B9-12-1 (FERM BP-6016) and 2E2-B3-1-3 (FERM BP-6014); to form an immunoconjugate; and, quantitatively detecting the immunoconjugate of the first monoclonal antibody and dihydropyrimidine dehydrogenase, so as to determine the level of dihydropyrimidine dehydrogenase in the biological sample from the patient to obtain a measure of susceptibility.
 59. The method of claim 58 wherein the immunoconjugate is detected with the aid of a label.
 60. The method of claim 58 wherein the first monoclonal antibody is adsorbed to a solid support and the immunoconjugate is formed on the solid support.
 61. The method of claim 60 wherein the presence or absence of the immunoconjugate on the solid support is detected by: adding a second antibody that specifically binds to dihydropyrimidine dehydrogenase; allowing the second antibody to specifically bind with any dihydropyrimidine dehydrogenase present in the immunoconjugate on the solid support to form a sandwiched conjugate; and, qualitatively or quantitatively detecting the presence or absence of the sandwiched conjugate with the aid of a label wherein the presence of the sandwiched complex is indicative of the presence of the immunoconjugate on the solid support.
 62. The method of claim 61 wherein the presence or absence of the sandwiched conjugate is detected by: adding a third antibody that specifically binds to the second antibody, wherein the third antibody is conjugated with a label thereby forming a labeled complex comprising the label bound to the solid support; and, determining the presence or the absence of the label bound to the solid support in the labeled complex.
 63. The method of claim 61 wherein the second antibody is a monoclonal antibody different from the first monoclonal antibody and wherein the second monoclonal antibody is produced by a hybridoma cell line selected from the group consisting of hybridoma cell lines 3A5-6-1 (FERM BP-6015), 4B9-12-1 (FERM BP-6016) and 2E2-B3-1-3 (FERM BP-6014).
 64. The method of claim 63 wherein the first antibody crossreacts with an antibody produced from the hybridoma cell line 3A5-6-1 (FERM BP-6015) and the second monoclonal antibody is produced from the hybridoma cell line 4B9-12-1 (FERM BP-6016).
 65. The method of claim 63 wherein the first monoclonal antibody crossreacts with an antibody produced from the hybridoma cell line 4B9-12-1 (FERM BP-6016) and the second monoclonal antibody is produced from the hybridoma cell line 3A5-6-1 (FERM BP-6015).
 66. The method of claim 63 wherein the first monoclonal antibody crossreacts with an antibody produced from the hybridoma cell line 3A5-6-1 (FERM BP-6015) and the second monoclonal antibody is one which crossreacts with an antibody produced from the hybridoma cell line 4B9-12-1 (FERM BP-6016).
 67. The method of claim 63 wherein the first monoclonal antibody crossreacts with a monoclonal antibody produced from the hybridoma cell line 4B9-12-1 (FERM BP-6016) and the second monoclonal antibody is one which crossreacts with a monoclonal antibody produced from the hybridoma cell line 3A5-6-1 (FERM BP-6015).
 68. A method for estimating the susceptibility of patients suffering from cancer to the treatment with antitumor medicaments in the series of 5-fluorouracil (5-FU) derivatives, which comprises: treating a biological sample from the patient with a monoclonal antibody comprising a first monoclonal antibody specifically recognizing human dihydropyrimidine dehydrogenase the to form an immunoconjugate wherein the first monoclonal antibody is produced by a hybridoma cell line selected from the group consisting of hybridoma cell lines 3A5-6-1 (FERM BP-6015), 4B9-12-1 (FERM BP-6016) and 2E2-B3-1-3 (FERM BP-6014); quantitatively detecting the immunoconjugate of the first monoclonal antibody and dihydropyrimidine dehydrogenase, so as to determine the level of dihydropyrimidine dehydrogenase in the biological sample from the patient; determining the level of pyrimidine nucleoside phosphorylase in the biological sample from the patient; and, calculating the ratio of the level of pyrimidine nucleoside phosphorylase and the level of dihydropyrimidine dehydrogenase to obtain a measure of susceptibility.
 69. The method of claim 68 wherein the immunoconjugate is detected with the aid of a label.
 70. The method of claim 68 wherein the first monoclonal antibody is adsorbed to a solid support and the immunoconjugate is formed on the solid support.
 71. The method of claim 70 wherein the presence or absence of the immunoconjugate on the solid support is detected by: adding a second antibody that specifically binds to dihydropyrimidine dehydrogenase; allowing the second antibody to specifically bind with any dihydropyrimidine dehydrogenase present in the immunoconjugate on the solid support to form a sandwiched conjugate; and, qualitatively or quantitatively detecting the presence or absence of the sandwiched conjugate with the aid of a label wherein the presence of the sandwiched complex is indicative of the presence of the immunoconjugate on the solid support.
 72. The method of claim 71 wherein the presence or absence of the sandwiched conjugate is detected by: adding a third antibody that specifically binds to the second antibody, wherein the third antibody is conjugated with a label thereby forming a labeled complex comprising the label bound to the solid support; and, determining the presence or the absence of the label bound to the solid support in the labeled complex.
 73. The method of claim 71 wherein the second antibody is a monoclonal antibody different from the first monoclonal antibody and wherein the second monoclonal antibody is produced by a hybridoma cell line selected from the group consisting of hybridoma cell lines 3A5-6-1 (FERM BP-6015), 4B9-12-1 (FERM BP-6016) and 2E2-B3-1-3 (FERM BP-6014).
 74. The method of claim 73 wherein the first monoclonal antibody is produced from the hybridoma cell line 3A5-6-1 (FERM BP-6015) and the second monoclonal antibody is produced from the hybridoma cell line 4B9-12-1 (FERM BP-6016).
 75. The method of claim 73 wherein the first monoclonal antibody is produced from the hybridoma cell line 4B9-12-1 (FERM BP-6016) and the second monoclonal antibody is produced from the hybridoma cell line 3A5-6-1 (FERM BP-6015).
 76. A method for estimating the susceptibility of patients suffering from cancer to the treatment with antitumor medicaments in the series of 5-fluorouracil (5-FU) derivatives, which comprises: treating a biological sample from the patient with a monoclonal antibody comprising a first monoclonal antibody specifically recognizing human dihydropyrimidine dehydrogenase to form an immunoconjugate wherein the first monoclonal antibody crossreacts with a monoclonal antibody produced by a hybridoma cell line selected from the group consisting of hybridoma cell lines 3A5-6-1 (FERM BP-6015),4B9-12 -1 (FERM BP-6016) and 2E2-B3-1-3 BP-6014); quantitatively detecting the immunoconjugate of the first monoclonal antibody and dihydropyrimidine dehydrogenase, so as to determine the level of dihydropyrimidine dehydrogenase in the biological sample from the patient; determining the level of pyrimidine nucleoside phosphorylase in the biological sample from the patient; and, calculating the ratio of the level of pyrimidine nucleoside phosphorylase and the level of dihydropyrimidine dehydrogenase to obtain a measure of susceptibility.
 77. The method of claim 76 wherein the immunoconjugate is detected with the aid of a label.
 78. The method of claim 76 wherein the first monoclonal antibody is adsorbed to a solid support and the immunoconjugate is formed on the solid support.
 79. The method of claim 78 wherein the presence or absence of the immunoconjugate on the solid support is detected by: adding a second antibody that specifically binds to dihydropyrimidine dehydrogenase; allowing the second antibody to specifically bind with any dihydropyrimidine dehydrogenase present in the immunoconjugate on the solid support to form a sandwiched conjugate; and, qualitatively or quantitatively detecting the presence or absence of the sandwiched conjugate with the aid of a label wherein the presence of the sandwiched complex is indicative of the presence of the immunoconjugate on the solid support.
 80. The method of claim 79 wherein the presence or absence of the sandwiched conjugate is detected by: adding a third antibody that specifically binds to the second antibody, wherein the third antibody is conjugated with a label thereby forming a labeled complex comprising the label bound to the solid support; and, determining the presence or the absence of the label bound to the solid support in the labeled complex.
 81. The method of claim 79 wherein the second antibody is a monoclonal antibody different from the first monoclonal antibody and wherein the second monoclonal antibody is produced by a hybridoma cell line selected from the group consisting of hybridoma cell lines 3A5-6-1 (FERM BP-6015),4B9-12-1 (FERM BP-6016) and 2E2-B3-1-3 (FERM BP-6014).
 82. The method of claim 81 wherein the first antibody crossreacts with an antibody produced from the hybridoma cell line 3A5-6-1 (FERM BP-6015) and the second monoclonal antibody is produced from the hybridoma cell line 4B9-12-1 (FERM BP-6016).
 83. The method of claim 81 wherein the first monoclonal antibody crossreacts with an antibody produced from the hybridoma cell line 4B9-12 -1 (FERM BP-6016) and the second monoclonal antibody is produced from the hybridoma cell line 3A5-6-1 (FERM BP-6015).
 84. The method of claim 81 wherein the first monoclonal antibody crossreacts with an antibody produced from the hybridoma cell line 3A5-6-1 (FERM BP-6015) and the second monoclonal antibody is one which crossreacts with an antibody produced from the hybridoma cell line 4B9-12 -1 (FERM BP-6016).
 85. The method of claim 81 wherein the first monoclonal antibody crossreacts with a monoclonal antibody produced from the hybridoma cell line 4B9-12-1 (FERM BP-6016) and the second monoclonal antibody is one which crossreacts with a monoclonal antibody produced from the hybridoma cell line 3A5-6-1 (FERM BP-6015). 